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In the following thesis, the syntheses of two natural products and of a natural products’ 
skeleton starting from (+)-sclareolide are presented. The second part of this thesis deals with 
the mechanistic studies on the organocatalytic α-chlorination of aldehydes.  
The first synthesis of (+)-vitepyrroloid A and B, which are labdane-type diterpene alkaloids 
isolated from the dried leaves of the shrub Vitex trifolia L. in 2017, is outlined. The natural 
products share an unprecedented 2-cyanopyrrole labdane core but differ in the substitution 
pattern of the pyrrole ring. Furthermore, (+)-vitepyrroloid A displayed an interesting biological 
activity. The low isolation yield prompted the development of an efficient synthesis. 
Therefore, the natural product was divided into two fragments.  
(+)-Sclareolide formed the base for the four-step synthesis of the alkyl iodide, which featured 
simultaneous methanolysis and tertiary alcohol elimination. The aryl bromide was synthesized 
starting from 3-bomopyrrole-2-carboxylic acid in three steps. The key step was the Csp2–Csp3 
cross-electrophile coupling of both fragments in a concise and protecting-group-free manner. 
This cross-coupling illustrates a rare application of this method in natural product synthesis. 
In the end, (+)-vitepyrroloid B was accessible by late-stage N-alkylation of its congener. 
  
The second project comprises the formal synthesis of actinoranone, a meroterpenoid isolated 
from the marine actinomycete strain CNQ-027 in 2013. This natural product constitutes of a 
tetralone-type polyketide connected with a bicyclic diterpenoid fragment and displayed a 
cytotoxicity against HCT-116 human colon carcinoma. This work addressed a new and more 
efficient formal synthesis in comparison to the two recently published synthesis routes. 
3,5-Dimethoxybenzaldehyde and (+)-sclareolide served as starting points for the two 
fragments envisioned by the disconnection between C14 and C15 of actinoranone. The first 
fragment, a vinyl iodide, was obtained in a concise five-step route featuring NEGISHI’s 
zirconium-catalyzed carboalumination/iodination sequence as the main step. The key step of 
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the tetralone fragment synthesis featured a LEWIS acid-mediated rigorous chirality transfer of 
the previously synthesized epoxy silyl ether to the β-siloxy aldehyde via a rearrangement 
inspired by YAMAMOTO. Subsequent WITTIG olefination led to the conjugated ester. The last 
steps to the actinoranone skeleton were similar to the already published routes. 
 
 
In the second part of this thesis, the mechanistic investigation of the organocatalytic α-
chlorination of aldehydes is discussed. Preliminary studies revealed a high catalyst loading in 
a procedure using N-chlorosuccinimide and MACMILLAN’s imidazolidinone catalyst. In this 
study, the α-chlorination of hydrocinnamaldehyde served as a model reaction. An unusual 
aminal intermediate, consisting of the substrate, the catalyst, and the chlorinating agent, was 
isolated and fully characterized. This work aimed at a deeper understanding of the aminal 
formation and its decay with the aid of 1H MR measurements. The results enabled the 
optimization of the α-chlorination by suppressing the aminal accumulation and enhancing the 




In der vorliegenden Arbeit sind die Synthesen von zwei Naturstoffen und von einem 
Naturstoffgerüst ausgehend von Sclareolid beschrieben. Der zweite Teil der Arbeit beinhaltet 
die mechanistische Untersuchung der organokatalysierten α-Chlorierung von Aldehyden.  
Die erste Synthese von (+)-Vitepyrroloid A und B, zwei 2017 aus den getrockneten Blättern 
des Vitex trifolia L. Busches isolierte Labdan-artigen Diterpenalkaloide, ist beschrieben. Sie 
besitzen einen beispiellosen 2-Cyanopyrrollabdankern, unterscheiden sich jedoch im 
Substitutionsmuster des Pyrrolringes. Darüber hinaus wurde eine interessante biologische 
Aktivität von (+)-Vitepyrroloid A festgestellt. Die geringe Isolationsmenge spornte uns für die 
Entwicklung einer effizienten Synthese an. Dafür wurde der Naturstoff in zwei Fragmente 
unterteilt. (+)-Sclareolid diente als Ausgangsverbindung für die vierstufige Synthese des 
Alkyliodides, welche eine Methanolyse und gleichzeitige Eliminierung des entstehenden 
tertiären Alkohols aufwies. Das Arylbromid wurde in drei Stufen ausgehend von 3-Brompyrrol-
2-carboxylsäuremethylester aufgebaut. Der Schlüsselschritt der Synthese war die präzise und 
schutzgruppenfreie kreuzelektrophilen Kupplung der beiden Fragmente. Die Csp2–Csp3-
Kreuzkupplung stellt ein seltenes Beispiel dieser Methode in der Naturstoffsynthese dar. (+)-
Vitepyrroloid B konnte durch eine Alkylierung des Stickstoffatoms von (+)-Vitepyrroloid A 
dargestellt werden.  
 
Das zweite Projekt beinhaltet die Formalsynthese von Actinoranon, ein Meroterpenoid, 
welches aus dem marinen Actinomycetstrang CNQ-027 2013 isoliert wurde. Dieser Naturstoff 
ist aus einem tetralon-artigen Polyketid verbunden mit einem bizyklischen Diterpen aufgebaut 
und besitzt eine Cytotoxizität gegenüber HCT-116 humanen Darmkrebs. Es wurde auf eine 
neue und effizientere Route zu diesem Naturstoff im Vergleich zu den beiden kürzlich 
veröffentlichten Routen abgezielt. 3,5-Dimethoxybenzaldehyd und (+)-Sclareolid bildeten die 
Ausgangsverbindungen für die Synthese der Fragmente von Actinoranon, welche durch den 
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retrosynthetischen Schnitt zwischen C14 und C15 entstanden. Das Vinyliodidfragment wurde 
durch eine fünfstufige Route kennzeichnend durch NEGISHI’s Zirconium-katalysierte 
Carboaluminierung/Iodierungssequenz erhalten. Der Schlüsselschritt der Tetralonsynthese 
war der durch Lewissäure unterstützte rigorose Chiralitätstransfer von dem dargestellten 
Epoxysilylether auf den β-Siloxyaldehyd durch eine von YAMAMOTO inspirierte Umlagerung. Der 
Aldehyd wurde sofort mittels WITTIG-Reaktion zum ungesättigten Ester umgesetzt. Die 
abschließenden Schritte zum Actinoranongerüst waren ähnlich den bereits veröffentlichten 
Routen. 
 
Der zweite Teil dieser Arbeit handelt von mechanistischen Untersuchungen der 
organokatalytischen α-Chlorierungen von Aldehyden. In einer vorausgehenden Studie wurden 
hohe Katalysatorbeladungen bei der Verwendung von N-Chlorsuccinimid und MACMILLAN’s 
Imidazolidinonkatalysator beobachtet. In dieser Studie diente die α-Chlorierung von 
Hydrozimtaldehyd als Modellreaktion. Ein ungewöhnliches Aminal-Intermediat, bestehend 
aus dem Substrat, dem Katalysator und dem Chlorierungsmittel, wurde isoliert und 
charakterisiert. Die Untersuchungen mittels 1H-NMR Spektroskopie zielten auf die Bildung und 
den Zerfall des Aminals ab. Die Ergebnisse dieser Untersuchungen führten zu einem 
optimierten System mit erhöhter Reaktionsrate und verminderter Katalysatorbeladung 




API active pharmaceutical ingredient 
9-BBN 9-borabicyclo[3.3.1]nonane 
BCE before common era 
bpy bipyridine 
CE common era 
DDQ 2,3-dichloro-5,6-dicyano-1,4-benzoquinone 
DFT discrete Fourier transform 
FDA Food and Drug Administration 
GC-MS gas chromatography-mass spectrometry 
GGPP geranylgeranyl pyrophosphate 
HMG-CoA 3-hydroxy-3-methylglutaryl-coenzym-A 
HTS high-throughput screening 
HV high vacuum 
IC50 median inhibitory concentration 
LD50 median lethal dose 
LLS longest linear sequence 
NCS N-chlorosuccinimide 
NMR nuclear magnetic resonance 
ROESY rotating-frame nuclear Overhauser effect 
SAR structure-activity relationship 
SOMO single occupied molecular orbital 
TBAF tetrabutylammonium fluoride 
TES triethylsilyl  
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 Sclareolide as a building block for     natural product syntheses 
 
      
 
 




1.1 General aspects of natural products  
1.1.1 The origin of natural products 
 
For centuries, humans relied on nature to provide for their basic needs, whether it was for the 
production of shelters and clothing, fertilizers, flavors and fragrances, and not at last, 
nutritional or medical purposes.[1-2] In particular, the discovery and utilization of biogenic 
compounds led to major advances in the health and nutrition sector over the last century. 
Especially, the supplementation of vitamins, the identification of natural toxins, and the 
introduction of drugs based on natural products in modern medicine improved life in terms of 
expectancy and quality.[3]  
Nature is an enormous source of small molecules, which are defined by a molecular weight 
smaller than 1 000 Da and have attained massive success related to health problems of our 
society (e.g., diabetes, cancer, obesity). Due to their small size, they are capable to pass the 
cell membrane and then affect or complement biological targets such as proteins and hence 
might regulate biological processes. With their inherent diversity, they are distinct from 
macromolecules such as proteins, nucleic acids, and most polysaccharides and serve as a tool 
proofing biological functions as well as promising leads for the development of therapeutic 
agents.[4] The naturally occurring small molecules are produced by living organisms such as 
plants, animals, or microorganisms.[5] The term “natural product” is mostly used to describe 
secondary metabolites which, in contrast to the primary ones like carbohydrates, lipids, 
proteins, and nucleic acids, are not essential for the normal growth, development, or 
reproduction of an organism. Secondary metabolites provide the general maintenance and 
homeostasis of an organism.[6] They can contribute to the organism’s survival by providing 
specific responses to competitors, pathogens, or predators; in the competition for 
environment and nutriments; in the inter- and intraspecies communication for mating, or for 
hunting and quorum signaling.[5] These selected natural substances are binding to protein 
receptors and thereby initiate a cascade process, which leads to the modulation of specific 
functions. Additional hypotheses for the origin of natural products have been proposed: 
secondary metabolites might have had a former functional role. They could have been 
products of accidental mutations or formed as by-products of the organism’s response to an 
external stimulus such as infestation.[2, 6] Naturally occurring small molecules are generally 
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divided into different classes of compounds: alkaloids, terpenoids, phenolics, polyketides, 
lipids, glycosides, nonribosomal peptides, phenanzines, and tetrapyrroles. They not only affect 
their actual target in animals, plants, or microorganisms but may also influence human cells.[7] 
They feature complex and diverse molecular structures which have been applied as medicines, 
flavorings, or recreational drugs.[8] In ancient times, indigenous tribes used natural substances 
for hunting, religious purposes, and medicaments. Not without a reason, it is told that nature 
is an ancient pharmacy. Owing to this, the pharmacological active natural products can be of 
therapeutic benefit for treating human diseases. The two main sources, namely plants and 
marine organisms, for these biologically active compounds are discussed in the following 
subchapter. 
 
1.1.2 Plant- and marine-derived natural products – a historical perspective 
 
Plants for medical treatment have been already used 60 000 years ago and still remain one of 
the main sources for pharmacologically active compounds in drug discovery.[9-10] Over 1 000 
plant-derived formulations were documented in Mesopotamia medicine and some of the 
used oils are still employed today for coughs and colds in the Egyptian medicine.[11] Around 
700 medicaments from plant origin were recorded in the Ebers Papyrus dating from 1 500 BCE 
in Egypt.[2] Other prominent examples are the herbals in Chinese medicine or the Indian 
Ayurvedic system.[11] The rational development of herbal drugs in the ancient Western world 
was driven by the Greeks and Romans around 100 CE. Finally, the Arabs combined the Greco-
Roman expertise with the knowledge about Chinese and Indian herbs in the Early Middle 
Ages.[2] Still today, the plant-based medicine continues to play an essential role in healthcare. 
This is highlighted by the fact that around 65% of the world population relies on plant-derived 
traditional medicine for primary health care as estimated by the World Health Organization 
(WHO) in 2002.[12] The evolution from herbal remedies to potent clinical drugs and therefore 
to active pharmaceutical ingredients (API) was a slow and gradual process that started in 1804. 
In this year, the German pharmacist F. SERTÜRNER isolated a highly potent alkaloid, which is 
nowadays still used as a painkiller, from the opium poppy Papaver somniferum (Figure 1) and 
named after the Greek god of dreams, morphine.[7] This first-time isolated natural product 
was the basis for many synthetic and natural analogs with similar relevant analgesic properties 
such as heroin, codeine, and oxycodone (Figure 1). 
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Figure 1: Structure of morphine, its direct derivatives, and opium poppy flower. Reprinted with permission of P. 
Robot.[13] 
In the last century, the receptor theory of drug action in which certain chemical compounds 
in extracts of plants specifically interact with the biological macromolecules in human bodies 
remodeled the way of thinking towards drugs as individual active substances instead of plants 
as remedies.[14] Thus, the active compounds of several traditional medicinal plants were 
elucidated. For instance, in 1820, French pharmacists isolated the antimalarial drug quinine 
from the bark of Cinchona species.[1] Before, it has already been used by indigenous groups in 
the Andes and later by the Spanish conquerors for the treatment of fevers. With the isolation 
and also the proper administration, quinine became the antimalarial treatment of choice over 
the powdered bark treatment; however, the structure has not been elucidated until 1908 
(Figure 2).[10] Another example of plant-derived medicine is the cardiotonic agent digoxin. It 
was elucidated from the extracted of foxglove, Digitalis purpurea, which was commonly used 
for the treatment of heart diseases (Figure 2).[1, 14] 
 
Figure 2: Structures of digoxin, quinine, and Aspirin®. 
The Greek physician Hippocrates already used willow trees and other plants for pain relieve 
at childbirth, but not until the 19th century the acidic component of the willow tree extracts, 
salicylic acid, was isolated. This natural product was optimized in terms of the pharmacological 
profile leading to the popular drug acetylsalicylic acid (Aspirin®) by Bayer in 1897 (Figure 2).[10] 
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Another successful example of a natural product as a source for medicine is the penicillin 
antibiotic agent, which was serendipitously discovered by FLEMING in 1929 from the 
filamentous fungus Penicillium notatum. The broad therapeutic use of penicillins in the 1940’s 
marked the beginning of the so-called “Golden Age” of antibiotics and led to the intensive 
investigation on nature as a source of novel bioactive compounds.[1, 5]  
Apart from plants, marine organisms serve as a versatile source for naturally active 
compounds. They do not possess a history as traditionally used medicine; however, there are 
some indications for their usage as dies and soil fertilizers by the Phoenicians.[1] The 
outstanding, prolific source of biodiversity in the sea has yet to be explored more intensively.  
Oceans cover around 70% of the Earth’s surface. Here, life originated about 3.5 billion years 
ago and developed a huge biodiversity which accounts for more than 95% of the whole 
biosphere.[15-16] Approximately 80% of the ocean’s area is accounted to the so-called deep sea, 
which starts around 200 m below the surface and extends down to 1 000 m and beyond. Its 
unique and extreme environment is characterized by high pressure, extreme temperatures, 
lack of light, extreme pH-values, toxic chemicals such as H2S, variable salinities, and oxygen 
concentrations.[17] These environmental conditions differ considerably from the terrestrial 
world, but microbes are capable of occupying almost every conceivable habitat for life. Under 
these extreme circumstances, the production of novel bioactive compounds is fostered.[15] 
Additionally, the struggle for space and survival is another driving force for the development 
of new and bioactive substances used in the defense of habitat.[18] The mentioned extreme 
conditions lead to superior natural products compared to the terrestrial-derived ones in terms 
of chemical novelty.[17] But only after the progression in deep-sea exploration, these novel 
natural products could be discovered. The emergent role of marine natural products is also 
manifested in the data of the year 2016 where 1277 new bioactive compounds from the sea 
were described in the literature.[19] It is undeniable that these compounds are attracting 
increasing attention as a consequence of their wide variety of biological activities such as 
antitumor,[20-22] antiviral,[23] anti-HIV,[24] antiangiogenesis,[25] antituberculosis activity,[26] 
among others. In addition to that, these products are highly potent as their marine 
environment causes rapid dilution.[27] Due to the technical advances such as sampling 
strategies and nanoscale NMR for structure determination, the discovery and isolation of 
marine natural product was more feasible and had considerable success in the last years.[17]  
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1.1.3 Natural products as lead sources for drug discovery  
 
Natural products are not only interesting because of their structural diversity, but moreover, 
they provide highly selective and specific biological activities based on their specific 
mechanisms of action. The HMG-CoA reductase inhibition exhibited by lovastatin and the 
tubulin-assembly promotion induced by paclitaxel are two prime examples. Therefore, 
naturally occurring compounds play a significant role in the identification of lead structures 
for the development of novel drugs.[4, 11] It is estimated that in the early 1900s around 80% of 
the medicines were derived from roots, barks, and leaves.[28] The rise of natural product-based 
drug candidates during the 20th century began with the elucidation of the active compounds 
in natural sources. In this regard, some well-known drugs[1] were developed from traditional 
medicine:  
• the antihypertensive agent reserpine (Raudixin®) derived from Rauwolfia serpentina, 
(used in Ayurvedic medicine against snakebites)  
• the synthetical basis for anti-asthma agents salbutamol (Ventolin®) and salmeterol 
(Serevent®) obtained from ephedrine (known in the traditional Chinese medicine)  
• the muscle relaxant tubocurarine chloride (Tubarine®) (basis of arrow poison curare of 
indigenous groups in the Amazon)  
Interestingly, less than 10% of the world’s estimated biodiversity has been tested in biological 
screenings.[29] Only 5–15% of the approximately 300 000 species of higher plants have been 
systematically, chemically, and pharmacologically investigated.[2] The marine environment as 
a source for novel drugs remains comparatively unexplored as outlined in the previous 
chapter. Its extensive study began in the mid-1970’s with the technological progress in deep-
sea exploration. In 1969, cytarabine (Cytosar-U®) was introduced as the first drug derived from 
a marine natural product to the medical anticancer market. This was followed by the antiviral 
drug vidarabine (Vira-A®) in 1976 and the analgesic agent ziconotide (Prialt®) in 2004.[5] 
Nevertheless, many interesting biologically active compounds suffer from poor 
pharmacological profiles; hence, synthetic modifications with respect to stability and 
bioavailability are sought. It is stated that 80% of the commercial drugs based on natural 
products require synthetic efforts to improve physiochemical properties in terms of 
pharmacokinetics/pharmacodynamics.[30] 
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The relevant contribution of natural products as sources of new drugs has been demonstrated 
in a review from NEWMAN and CRAGG dealing with the development of approved drugs from 
1981–2014 (Figure 3). They revealed that 67% of the 1211 new chemical entities (NCEs, a drug 
that contains no already approved active moiety by the FDA) formally are derived from a 
synthetic origin. Within these 67%, 18% correspond to synthetic molecules containing 
pharmacophores derived from natural products (S* and S*/NM) and 14% mimic or model a 
natural product inhibitor of the molecular target of interest (NM). Hence, only 35% are of 
purely synthetic origin (S). Their analysis also showed that 83% of new approved anticancer 
drugs and 78% of anti-infectives were either per se or were based on natural products. The 
data points out the dominant role of the biologically active natural substances for these two 
categories. On the other side, it displays the drop of natural products as new drugs in 




N = unaltered natural product 
NB = botanical drug 
ND = natural product derivative 
S = synthetic drug 
S* = synthetic drug (natural   
         product pharmacophore) 
NM = mimic of natural product 
Figure 3: Approved small-molecule drugs from 1981–2014; n = 1211.[4] 
The reason for the decline can be traced back to the circumstance that the industry embraced 
the era of combinatorial chemistry and high-throughput screening (HTS) in the last two 
decades.[31] It was assumed that the chemical assembly of as many substances as possible by 
synthesis robots and trawling through vast libraries of small molecules with rather simple 
structures by automated procedures will identify new lead compounds against biological 
targets; however, this approach showed little success.[32-33] In this period, only one de novo 
combinatorial chemistry-synthesized drug, sorafenib (Nexavar®), which treats renal cell and 









N NB ND S S/NM S* S*/NM




Figure 4: The structure of only de novo synthesized drug sorafenib. 
Despite the great success of natural products in drug discovery, they are substantially 
underrepresented in current small molecule-based compound libraries. For a successful 
design of drug discovery program based on natural products, four main elements are thought 
to be crucial: acquisition of biomass, effective screening, bioactivity-driven fractionation, rapid 
and effective structure elucidation.[2] These procedures still remain challenging. Next to this 
time-demanding task, a limited supply of the natural sources, low isolation yield, and 
structurally complex molecules for modifications and/or synthesis are the main factors. 
Although the development of new technologies was embraced,[34] the HTS hit-rate lies only 
around 0.1% and in most cases, the identified hit is not suitable to become a lead structure 
for drug development due to the lack of activity and selectivity.[10] Moreover, the quality and 
outcome of HTS strongly depend on the chemical and structural diversity of the screened 
compound library. In this regard, the compound libraries based on combinatorial chemistry 
only cover a limited chemical space in comparison to already approved drugs and natural 
products.  
It was shown that the greater number of sp3-centers and higher structural complexity that are 
typical in natural products leads to higher success rates in drug discovery campaigns. 
Prominent examples of this hypothesis are Taxol® and Rapamycin® whose impact in biology 
and therapy could never be predicted a priori.[35] The main differences between natural 
products and approved drugs in comparison to components from combinatorial chemistry 
libraries are that the former are usually less hydrophobic and include less aromatic moieties; 
they have a higher number of chiral centers; more O- and less N-, S-, and halogen atoms; as 
well as higher levels of three-dimensionality and structural rigidity (Figure 5).[10, 14] It is stated 
that about 40% of the molecular scaffolds found in natural products are missing in today’s 
medicinal chemistry contingent.[34] Overall, these failures of the last decades reflect that we 
are far from the vision to produce a drug candidate by rational design on a computer or by 
virtual screening of chemical space. [36] Natural products provide in general a greater structural 
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diversity than the standard combinatorial chemistry libraries can create or modulate and 
hence possess major opportunities to bind to a range of assay targets.[29] 
Figure 5: Property diagrams of natural products (—), drugs (……), and synthetic (from combinatorial chemistry) 
compounds (-----).[10] 
 
An alternative approach that the pharmaceutical industry is currently pursuing is the 
combinatorial chemistry- and diversity-oriented synthesis. Herein the goal is to preselect a 
range of structurally diverse molecules starting from a common core that is elaborated 
following the principle of combinatorial chemistry and therefore provide a large and diverse 
compound library. However, these libraries possess a small hit rate compared to natural 
products and additionally potential side effects arise due to the less specific binding of these 
still rather simple molecules.[37-38] Natural products are only represented in 1% of all existing 
libraries due to the incompatibility of HTS with their solubility and self-fluorescence.[35, 39] New 
technological advances and development of new methods such as combinatorial biosynthesis 
or improved natural product sourcing are expected to overcome these drawbacks in the 
future.[40] Despite pharmaceutical companies have abandoned the research on natural 
products, they still provide a major source of new drugs candidates and consequently will 
secure their future on account of their unbeatable potencies.[41-42] In an essay on “Advancing 
the Drug Discovery and Development Process”, NICOLAOU made an interesting statement 
concerning the role of natural products in the future.[43]  
“The three-dimensional structures of natural products and their wealth of chiral centers 
should serve as an inspiration and motivation for drug designers. The dimensionality and 
chirality of biological receptors and the fact that natural products have evolved along and 
against such biomolecules explains their divers, potent, and often selective biological 
properties. Employing them and molecules like them as leads and introducing some of their 
structural features in drug designs makes good sense and should be a complementary 
approach to the currently employed drug design” 
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Referring to NICOLAOU’s statement, another perspective on natural products is given in a 
review of CRANE and GADEMANN. Here, they evaluate an approach based on natural product 
derived fragments which display a reduced molecular weight, structural complexity, and 
reduced number of synthetic steps while retaining or even improving the key biological 
parameters (e.g., bioactivity, pharmacokinetics, solubility, etc.).[30] An interesting example for 
this structural simplification concept is the development of bryostatin analogs. The marine 
natural product possesses a large range of biological activities and either has been or is 
currently being evaluated in 37 clinical trials for the treatment of various cancer types.[30] 
Studying the mode of action led to the assumption that the bigger part of the structure acts 
as a framework for three distinct oxygen atoms, two alcohols, and a lactone unit. The 
simplification of the so-called scaffold region (upper part of the molecule) led to analog A 
(picolog) which was found to be more potent than the parent compound and practically 
suitable for large-scale synthesis (Figure 6).[37] 
 
Figure 6: Structural simplification of bryostatin 1 to analog A.[37] 
The described conceptional approach is similar to the one reported by WALDMANN, the biology-
oriented synthesis. This method is based on the compatibility analysis of structures of ligand-
sensing cores embedded in protein domain folds with scaffold structures of natural products. 
Therefore, it is aimed for the preparation of scaffold-based compound libraries by reduction 
of the structural complexity while the bioactivity should be retained.[44] Several examples 
demonstrated the potential of this approach in bridging the gap between computational 
methods and compound library synthesis.[45] In spite of the trend in pharmaceutical 
companies, one should not neglect the fact that nature carried out its own version of 
combinatorial chemistry and HTS to reach an optimum of biologically active compounds for 
over three billion years.[37] Moreover, the opinions in the chemical society are suggesting a 
renaissance of natural products due to the failure of alternative drug discovery methods to 
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provide new lead compounds for therapeutic key areas: immunosuppression, anti-infections, 
and metabolic diseases.[30, 37, 41, 46]  
1.1.4 The role of total and semisynthesis in drug development 
 
As mentioned in the previous chapter, a major drawback in the use of natural products as 
sources for drug development is the low isolation yield and limited supply from its natural 
resource. Especially, in the case of marine natural products, the isolation process itself is quite 
extensive. However, despite small isolable quantities, they possess attractive biological 
activities and chemical structures which make them an interesting target for organic synthesis. 
In the drug discovery process, lead structures are identified by testing substances against 
specific biological targets which have been identified to be involved in diseases or 
malfunctions. After identification of such leads, there is a need to generate larger amounts of 
the material for further modification, biological testings, and evaluation of its structure-
activity relationship (SAR). The large-scale supply of the desired compound can be generally 
pursued by microbial fermentation, biotechnology, or total synthetic approaches (Figure 7).[17] 
 
Figure 7: The discovery of a lead compound from marine sources. Reprinted with permission of Luesch et al. 
Copyright 2011 Future Science.[17] 
A total synthesis is thereby an important tool for large-scale supply and lead optimization. The 
desired product is chemically synthesized starting from readily accessible building blocks. 
Besides the total synthesis, a semisynthetic approach—using chemical and molecular 
biological methods—can also deliver a large amount of the target compound. Herein an 
advanced intermediate is biosynthetically produced and further manipulated in a 
chemoselective, regioselective, and stereoselective fashion to give the desired molecule. This 
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approach is usually used when the precursor molecule is highly structurally complex, 
expensive, or not readily accessible by a total synthetic route. The chemotherapy drug 
paclitaxel (Taxol®) and the antibiotic derivatives of penicillin are examples of products 
successfully obtained through semisynthesis (Scheme 1).[47] 10-deacetylbaccatin III, which was 
isolated from a yew tree, is the starting point for the synthesis of paclitaxel. On the other side, 
the fermentation brew of the Penicillium mold gives 6-aminopenicillanic acid as a key building 
block for the synthesis of various penicillins. 
 
Scheme 1: Paclitaxel (Taxol®) and benzylpenicillin (Penicillin G®) and their biosynthetic precursors.[47] 
In most cases, the lead natural compound is not selective enough against the desired target 
and therefore has to be further derivatized.[47] Semisynthetic approaches tend to be 
economically advantageous because of their shorter preparation. On the other hand, late-
stage modifications are challenging due to the structural complexity of the semisynthetic 
precursors. A total synthetic approach can be more flexible as it allows access to a wider range 
of diversity during synthesis. As an example, the first oral contraceptive, norethisterone 
(Aygestin®), was initially accessed semisynthetically from estrone. SAR studies led to the 
discovery of the more active levonorgestrel (Plan B®) and gestodene (Femodene®). The 
presence of the unnatural 13-ethyl group prevented their synthesis from the natural steroid 
skeletons, thus, imposing the use of a total synthetic approach (Scheme 2).[47]   
 
Scheme 2: Norethisterone, levonorgestrel, and gestodene with one possible precursor.[47] 
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There are also examples where the total synthesis of a molecule led to the discovery of a 
semisynthetic approach, as reported with the antitumor agent ecteinascidin 743 (Yonelis®), a 
highly potent antitumor drug for chemotherapy. The target molecule could be obtained in 23 
steps starting from the fermentatively accessible cyanosafracin B, a fragment inspired by 
COREY’s synthesis (Scheme 3).  Another outstanding example is (+)-discodermolide (Scheme 3). 
Novartis has installed a hybrid synthesis combining strategies of existing total synthetic 
approaches. They produced this highly potent microtubule-stabilizing agent in 39 steps in total 
(26 LLS) in a 60 g scale. Unfortunately, the compound was halted in Phase II of the clinical 
trials.[47] 
 
Scheme 3: Semisynthesis of esteinasceidin 743 (Yonelis®) from its precursor cyanosafracin B and (+)-
discodermolide.[47] 
 
These examples show that despite the negative attributes associated with total syntheses, 
such as cost-inefficient strategies, lengthy synthetic routes with long development time, low 
overall yield, and impracticality of scale-up, the total and semisynthetic methods are an 
integral part of modern industrial research and drug development.[47] Above that, in cases 
where no suitable natural occurring precursors are accessible and the supply of the lead 
substance cannot be guaranteed by natural sources, total synthesis represents the only 
alternative. Moreover, the totally synthetic approach allows proving the preliminary structural 
assignment or the resolution of unspecified stereocenters. There were several cases in which 
the initial structural proposal had to be revised.[48-52] Overall, total synthesis is a great 
academic tool to extend the basic chemistry knowledge, and in addition, it is a starting point 
for the discovery of novel reactions and development of efficient chiral and catalytic 
reactions.[1] 
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1.2 The natural products (+)-vitepyrroloid A and B  
A synthetic approach to natural products aims for a deeper understanding of the chemical and 
physical features of the targeted molecule, as it was outlined in the previous chapters. In this 
context, the natural products (+)-vitepyrroloids A and B attracted our attention in virtue of 
their unprecedented structures and interesting biological activity. 
The widespread shrub Vitex trifolia L. of the family of Verbenaceae is known in the southern 
provinces of mainland China for its antioxidant, tracheospamolytic, cytotoxic, and 
trypanocidal activity.[53] Its fruits have already been used in the traditional treatment of colds, 
migraine, headache, and rheumatism.[54] In 2017, XU and co-workers reported the isolation of 
four diterpenoid alkaloids from the dried leaves of this shrub, namely vitepyrroloids A–D. The 
congeners contain an unprecedented 2-cyanopyrrole labdane core but differentiate in the 
substitution at the pyrrole nitrogen and/or in the oxidation pattern of the decalin system 
(Figure 8, 1a–1d). The absolute configuration was determined by spectroscopic and X-ray 
crystallographic analysis.[55] In particular, (+)-vitepyrroloid A exhibits a cytotoxic activity 
against a human nasopharyngeal carcinoma cell line (CNE1) with an IC50 of 8.7 µM. 
Nasopharyngeal carcinoma is a rare disease worldwide but is more common in certain 
geographic areas such as Southern Asia and North Africa. An effective chemotherapy against 
this tumor is urgently required since the healing prognosis of this carcinoma at advanced stage 
remains poor and early diagnosis is rare.[56-57] However, the low isolation yield (30 kg of air-
dried leaves gave 8.5 mg of the natural product) makes this biological material barely 
available. Therefore, a synthetic approach to these natural products would access satisfying 
amounts of substrates to perform extensive biological tests.  
 
Figure 8: Structure of vitepyrroloids A–D (1a–1d). 
Until now, no synthesis has been published for vitepyrroloids A and B despite their interesting 
structure and biological features. The biosynthesis of these compounds was described along 
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with their isolation in a report by XU and co-workers (Scheme 4).[55] They assumed that the 
vitepyrroloids might be derived from geranylgeranyl pyrophosphate (GGPP, 2) which after 
acid-catalyzed cyclization, leads to (+)-copayl PP (3). This process would be followed by 
sequential oxidation and reduction. Afterward, reaction with ammonia, L-glutamic, or L-serine 
followed by decarboxylation would give the intermediate 5. Conversion of amine 5 to 7 could 
be achieved via SCHIFF base formation and MANNICH reaction. Final oxidation followed by loss 
of CO2 and H2O leads to vitepyrroloid A and after esterification with ethanol to vitepyrroloid 
B. Oxidation and acetylation of the intermediate 1a would give the remaining vitepyrroloids. 
 
Scheme 4: Biosynthesis of vitepyrroloid A (1a) and B (1b).[55] 
  
PART A: INTRODUCTION 
 
16 
1.3 The natural product actinoranone 
Streptomyces is a genus of the order of actinomycetes derived from the phylum of 
Actinobacteria, which can be of marine or terrestrial habitat.[58] As part of an expedition 
program devoted to studying the marine actinomycetes, by now a largely unexplored 
compound class, the group of FENICAL isolated the natural product actinoranone from the 
strain CNQ-027 in 2013. This strain shares 97.6% 16S rRNA gene sequence identity with the 
known species Streptomyces marinus, thus, might represent a new species adapted to life in 
the sea.[59] The novel meroterpenoid exhibits a significant in vitro cytotoxicity against HCT-116 
human colon carcinoma cells with an LD50 of 2.0 μg/mL. Colon cancer is the fourth most 
common cause for cancer death beyond lung, liver, and stomach tumors.[60] More than 1.2 
million people receive the diagnosis and around 600 000 die from this disease every year.[61]  
Actinoranone possesses an unprecedented dihydronaphthalene polyketide skeleton and 
belongs to the meroterpenoids that are defined as compounds of mixed polyketide-terpenoid 
origin. This term was introduced in 1968 by CORNFORTH and differentiated 
polyketide─terpenoids from non-polyketide─terpenoids.[62] The structure of the natural 
product was elucidated by mass spectrometry and NMR spectroscopy. By applying a modified 
MOSHER’s ester method and ROESY NMR analyses, the relative configuration of the bicyclic 
terpenoid unit (C5, C9, and C10) was determined and the absolute configurations at C15 was 
initially predicted as R. The absolute configuration at configuration at C8’ (syn relative to C15) 
was deduced by interpretation of the ROESY NMR analysis of the protons attached to C15 and 
C8´.[63] Recently, YE and co-workers accomplished the first synthesis of actinoranone and three 
diastereomers, thereby, giving proof of the relative configuration at the decalin skeleton and 
revising the stereochemistry at C15 and C8’ (anti-relationship). In the end, the configuration 
was assigned as 5S, 9S, 10S, 15 R, 8’S (Figure 9, 9).[64]   
 
Figure 9: Originally proposed and revised structure of actinoranone (9).  
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In actinoranone, as well as in (+)-vitepyrroloid A and B (chapter 1.2), the labdane-type 
diterpenoid unit is present. In general, labdane-related diterpenoids comprise over 5 000 
known natural products having in common the substituted decalin structural motif.[65] This 
structural motif is often found in natural products possessing important pharmaceutical 
activities: (─)-15-oxopuupehenol with antimalarial activity, widendiol A inhibits the cholesteryl 
ester transfer protein, acuminode cytotoxicity against melanoma, rhinocerotinoic acid with 
anti-inflammatory activity, (+)-zonarol a fungitoxic hydroquinone, (+)-zerumin B with 
antitumor activity against human tumor cell lines, and more.[66]  
 
1.3.1 State of the art 
 
Regarding actinoranone, two syntheses were independently reported in 2017 by the groups 
of PASTRE[67] and YE.[64] In terms of retrosynthetic analysis, both synthetic studies evaluated the 
same disconnection of the allylic C–C bond within the vinyl alcohol unit, thus, leading to the 
corresponding vinyl iodide 10 and bicyclic alcohol 11 as main leading fragments (Scheme 5). 
The final coupling would employ the nucleophilic addition of the vinyl metal species derived 
from fragment A to the aldehyde derived from fragment B. At the end, C–H benzylic oxidation 
would give the natural product. 
 
Scheme 5: General retrosynthetic disconnection strategy employed by the YE and PASTRE groups.[64, 67] 
 
The first synthesis of actinoranone, carried out by YE and co-workers, proposed (+)-sclareolide 
as starting point for the synthesis of fragment A.[64] They assumed that the vinyl iodide 10 
might be accessible from alkyne 12 by a NEGISHI’s carbonzirconation/iodination sequence 
which in turn could be derived from (+)-sclareolide (13) through several transformations and 
oxidation steps (Scheme 6). Fragment B was traced back to a 3,5-dimethoxyphenylacetic acid 
functionalized with a chiral auxiliary unit (15); thus, stereochemical information could be 
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introduced via an EVAN’s asymmetric allylation. Further transformations and a FRIEDEL–CRAFTS 
type cyclization would lead to the target fragment B (Scheme 6).  
 
Scheme 6: Retrosynthetic analysis of the YE group.[64] 
YE’s route started from commercially available (+)-sclareolide (13) which was converted into 
alcohol 16 in seven steps following a known literature procedure.[68] Afterwards, the protected 
alcohol was transformed to the iodide 18 by a deprotection/FINKELSTEIN-like reaction sequence 
using sodium iodide as nucleophile. Protection of the secondary alcohol as TES-ether allowed 
alkynylation employing TMS acetylene. Subsequent removal of the of the silyl groups with 
TBAF yielded the terminal alkyne moiety and the secondary alcohol 12.  
 
Scheme 7: Synthesis of fragment A (10) by YE’s group.[64] 
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In the following step, a cis-carbozirconation/iodination protocol from NEGISHI was applied to 
convert the alkyne into the desired vinyl iodide unit 19. The secondary alcohol was finally 
eliminated affording fragment A in 15 steps with 11% overall yield (Scheme 7). 
The preparation of fragment B commenced with the transformation of commercially available 
3,5-dimethoxyphenylacetic acid (20) into (S)-oxazolidinone imide 15 in two steps. By applying 
an EVAN’s asymmetric alkylation, the allyl unit was enantioselectively introduced. The auxiliary 
was cleaved and after protection of the resulting alcohol, the terminal double bond was 
selectively hydroborated with the sterically demanding 9-BBN. Oxidative work-up led to 
primary alcohol 22 which was further oxidized using PARIKH–DOERING conditions. Next, FRIEDEL–
CRAFTS reaction forged the second ring (23). Finally, hydrogenation and deprotection with 
TBAF led to the bicyclic fragment B in a total of nine steps with 15% overall yield (Scheme 8). 
 
Scheme 8: Synthesis of fragment B (11).*
To connect the two fragments, the vinyl iodide 10 was treated with nBuLi leading to a halogen-
metal exchange. Thus, the freshly prepared aldehyde 24 from 11 using DESS–MARTIN 
periodinane as oxidation agent was directly added to the in situ prepared vinyllithium species 
leading to the formation of allyl alcohol 25 with a diastereomeric ratio of 5:1. MITSUNOBU 
reaction inverted the configuration at the secondary alcohol. Finally, benzylic oxidation with 
DDQ and ester cleavage led to the natural product actinoranone (9, Scheme 9). 
                                                     
* There are no yields and dr given in the publication of the YE group as their original reported synthesis route led 
to the wrong diastereomer of actinoranone. 15% overall yield and dr = 10:1 belong to their published route. 




Scheme 9: Endgame of the synthesis of actinoranone (9).[64] 
PASTRE et al. published an alternative formal synthesis[67, 69] of actinoranone in 2017 which was 
based on the same retrosynthetic disconnection leading to the same fragments A and B as 
proposed by YE. They envisioned to access the vinyl iodide by a decarboxylative iodination of 
the ester which was derived from the commercially available (+)-sclareolide by HORNER–
WADSWORTH–EMMONS olefination and E2 elimination. Fragment B should be obtained by 
applying Ru-catalyzed cross-metathesis and Ir-catalyzed KRISCHE hydroxymethylation to the 
allylic acetate 28 (Scheme 10). 
 
Scheme 10: Retrosynthetic analysis of the NOVAES and PASTRE.[67, 69] 
The formal synthesis commenced with the transformation of (+)-sclareolide (13) into its 
epimer with the aid of sulfuric acid. Then, WEINREB amide 30 was obtained after treatment of 
lactone 29 with Me2AlCl followed by E2 elimination which produced the desired trisubstituted 
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endo-olefin. The WEINREB amide 30 was reduced to aldehyde 31 which was further 
transformed into the corresponding nitrile by application of VAN LEUSEN reaction. In the next 
step, GRIGNARD addition to the nitrile moiety gave the ketone 32 which was then subjected to 
a HORNER–WADSWORTH–EMMONS olefination. The route to fragment A for the polyketide unit 
was finished by hydrolysis of the ester 27 and final decarboxylative iodination. Fragment A 
was obtained in nine steps starting from (+)-sclareolide with 3.4% overall yield (Scheme 11). 
 
Scheme 11: Synthesis route of fragment A (10).[67, 69] 
The approach to the tetralin system started with the Ir-catalyzed enantioselective 
hydroxymethylation of the allylic acetate 28 which was previously prepared in two steps from 
3,5-dimethoxybenzaldehyde. This was followed by alcohol protection and then cross-
metathesis with crotonaldehyde using GRUBBS II catalyst to give the enal 35. After 
hydrogenation of the double bond, the route of PASTRE was identical to the approach of the YE 
group. Briefly, FRIEDEL–CRAFTS reaction, hydrogenation, and deprotection with TBAF led to 
fragment B in 9 steps in total and 3.5 % overall yield (Scheme 12).  




Scheme 12: Synthesis route of fragment B (11).[67, 69] 
In summary, the synthesis of YE and co-workers consists of 29 steps in total and 19 steps 
longest linear sequence (LLS). They needed seven steps to install the desired trisubstituted 
endo-double bond in the synthesis of fragment A leading to a rather low overall yield of 11%. 
The required stereo information in fragment B was introduced by a stoichiometric auxiliary 
approach with modest diastereoselectivity. On the other hand, PASTRE and co-workers 
accomplished the formal synthesis in 20 steps (11 steps LLS). In this case, they epimerized the 
natural compound (+)-sclareolide and performed an E2 elimination to get to the endo-alkene 
in a rather low yield. Further transformations led to fragment A in low 3.4% overall yield. Ir-
catalyzed enantioselective hydroxymethylation and cross-metathesis were used for the key 
steps in the synthesis of fragment B. Here, the route suffered from low yields in both steps 
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2) SCIENTIFIC GOALS 
The class of labdane-type diterpenoids possesses an attractive structural motif displaying 
important pharmaceutical activities. Two new representatives, (+)-vitepyrroloids A (1a) and B 
(1b), have been isolated and their biological activity against a nasopharyngeal carcinoma was 
evaluated. However, more data and material are required to assess a complete biological 
screening, thus, strengthening the need to find synthetic strategies towards this class of 
natural products. The following work addresses the first synthetic approach towards these 
natural products by utilizing a terpene feedstock as a suitable building block, hence, 
minimizing C–C-bond forming reactions. 
In this dissertation, a retrosynthetic cut between C12 and C13 of (+)-vitepyrroloid A and B was 
proposed (Scheme 13). This disconnection led to the bromo-pyrrole 37 and the iodide 39 as 
main fragments. With this cut, it was opted for a late-stage Csp2–Csp3 cross-electrophile 
coupling for the fusion of iodide 39 and bromide 37. The bromo-pyrrole would be prepared in 
few manipulations from commercially available 3-bromopyrrole-2-carboxylic acid methyl 
ester (38). (+)-Sclareolide (13) was expected to be a convenient terpene feedstock as starting 
building block. Vitepyrroloid B should be accessible by manipulation of vitepyrroloid A or by 
using a suitable N-alkyl bromo-pyrrole fragment for the cross-electrophile coupling. 
 
Scheme 13: Retrosynthetic analysis of (+)-vitepyrroloid A (1a) and B (1b). 
The meroterpenoid actinoranone (9) also features a labdane-diterpenoid unit, which is 
connected to a tetralin system. In preliminary studies, an interesting biological activity against 
HCT-116 human colon carcinoma was found.[63] Colon cancer is the fourth most common 
cause of fatal cancer beyond lung, liver, and stomach; hence, the development of new active 
agents for treatment is still crucial.[70] In 2017, two independent syntheses, based on the same 
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retrosynthetic cut, towards actinoranone were published. YE and co-workers’ approach 
consisted of 29 steps in total and 14 in the longest linear sequence.[64] PASTRE’s route towards 
the skeleton of actinoranone comprised of 20 steps with 11 in the longest linear sequence.[67] 
In general, the polyketide motif was assembled in a concise manner; however, the diterpenoid 
unit was obtained after rather long-winded approach. Whilst some synthetic effort has been 
carried out, the published syntheses lack generality and efficiency. Identification of a shorter 
and more concise method became a key objective in the following thesis. 
Retrosynthetically, actinoranone was planned to be disconnected accordingly to YE and PASTRE 
leading to the same vinyl iodide and bicyclic alcohol fragments (10 and 11, respectively). The 
alkene in fragment A was thought to be synthesized from the corresponding alkyne 41 by 
carbozirconation and subsequent iodination. Alkyne 41 should be prepared from 
commercially available (+)-sclareolide (13) with a few modifications. Relating to fragment B, it 
was envisioned to access the bicyclic alcohol 11 from 3,5-dimethoxybenzaldehyde. At the 
outset, it was expected to install the stereo information via an asymmetric SHARPLESS 
epoxidation, which might then be transferred to a β-siloxy aldehyde through a by YAMAMOTO[71] 
introduced organoaluminum-promoted rearrangement (Scheme 14). 
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3) PUBLICATIONS AND MANUSCRIPTS 
In the following section the published article and the submitted manuscript are listed, and the 
contributions of the author are detailed. 
 
3.1 Synthesis of (+)-Vitepyrroloid A and (+)-Vitepyrroloid B by Late-Stage Ni-Catalyzed 
C(sp2)─C(sp3) Cross-Electrophile Coupling 
M. Menger, D. Lentz, M. Christmann, J. Org. Chem. 2018, 83, 6793─6797. 
Reprinted with permission from J. Org. Chem. 2018, 83, 6793─6797. Copyright (2018) 
American Chemical Society. 




A concise and scalable five-step synthesis of (+)-vitepyrroloid A and a six-step synthesis of (+)-
vitepyrroloid B are reported. Both natural products are interesting labdane diterpenoid 
alkaloids from Vitex trifolia L. The presented approach features a Ni-catalyzed Csp2─Csp3 cross-




I developed the synthetic strategy towards (+)-vitepyrroloid A and (+)-vitepyrroloid B and 
afterwards executed all reactions. All analytical data such as NMR, IR, and ESI-MS were 
evaluated by me. The crystal for X-ray crystallographic analysis were provided by me. I 
developed and wrote the general outline of the manuscript with assistance of the 
corresponding author. 
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3.2 Formal Synthesis of Actinoranone Using a Racemization-Free One-Pot Semipinacol 
Rearrangement/Wittig Reaction 
M. Menger, M. Christmann, manuscript in preparation. 
Abstract: 
The syntheses of the tetralone type polyketide and bicyclic diterpenoid fragments of the 
natural product actinoranone are reported. Key feature of this route is the exceptional 
rigorous chirality transfer by applying a organoaluminum-promoted rearrangement 
introduced by YAMAMOTO—a siloxy-epoxide rearrangement reaction—followed by subsequent 
WITTIG homologation in the synthesis of the polyketide fragment. This straightforward 




I developed the general synthetic route towards the natural product actinoranone and 
executed all synthetic steps. Analytical data such as NMR, IR, and ESI-MS were evaluated by 
me. The manuscript was written by me with assistance of the corresponding author. 
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Formal Synthesis of Actinoranone Using a Racemization-Free One-
Pot Semipinacol Rearrangement/Wittig Reaction 
M. Menger and M. Christmann* 






The syntheses of the tetralone type polyketide and bicyclic diterpenoid fragments of 
actinoranone are reported. Key feature of this route is the exceptional rigorous chirality 
transfer by applying a organoaluminum-promoted rearrangement introduced by Yamamoto—
a siloxy-epoxide rearrangement reaction—in the synthesis of the polyketide fragment. This 
straightforward approach is giving access to the skeleton of the marine natural product in 16 
steps (11 steps for LLS). 
 
1. Introduction  
The marine environment is becoming the number one source for the discovery of new 
potentially bioactive molecules and drug leads.1 The diversity of life in the terrestrial habitat 
is extraordinary, but the greatest biodiversity and chemical novelty occurs in the oceans.2-4 
Marine actinomycetes are a prolific source of secondary metabolites. In general, this 
Actinobacteria subclass is comprising half of the discovered secondary metabolites, in 
particular, antibiotics,5 antitumor agents,6 immunosuppressive agents,7 and enzymes.8 A large 
number of terrestrial actinomycetes have been screened and isolated but the distribution of 
this compound class in the sea is largely unexplored. The vast majority of the marine 
actinomycetes are derived from the single genus Streptomyces. This is the largest genus of 
Actinobacteria and is widely spread in marine and terrestrial ecosystems.9 Interestingly, the 
genus Streptomyces alone accounts for the majority the antibiotics used today.10-11 
In recent years, expanding studies of marine actinomycetes have yielded quite a number of 
bioactive molecules with diverse chemical structures.12 As part of this program, Fenical and 
PART A: PUBLICATIONS AND MANUSCRIPTS 
 
33 
co-workers isolated actinoranone from the marine actinomycetes strain CNQ-027 in 2013.13 
This strain shares only 97.6% 16S rRNA gene sequence identity with the genus Streptomyces 
marinus, hence might represent new species adapted to live in the sea.14 The isolated 
cytotoxic meroterpenoid is constituted by a tetralone type polyketide and a bicyclic 
diterpenoid fragment connected by a single C-C bond between C15 and C8´and displayed an 
LD50 value of 2.0 µg/mL against HCT-116 human colon carcinoma.13 The first total synthesis of 
actinoranone by Yu15 in 2017 revised the initial proposal for 1 based on ROESY and Mosher´s 
ester analyses and revealed a anti relative configuration for C15 and C8´ (Figure 1). A second 
formal synthesis of the natural product was performed by the group of Pastre in the same 
year.16 With regards to the retrosynthetic analysis, disconnection between C14 and C15 
recognized vinyl iodide 2 and the bicyclic alcohol 3 as key fragments in the synthesis of this 
unusual marine natural product (Scheme 1). Fragment 2 could be clearly obtained from the 
sesquiterpene lactone sclareolide17-25 while synthesis of alcohol 3 proved to be ambiguous.  
 
Figure 10: Originally proposed and revised structure of actinoranone 1. 
The synthesis of Ye and co-workers consisted of 29 steps in total and 19 in the longest linear 
sequence. They introduced the stereocenter in the bicyclic fragment by an auxiliary-route with 
modest diastereoselectivity. In addition to that, the Pastre group accomplished a formal 
synthesis in 20 steps (11 steps LLS). They applied a different strategy to install the 
trisubstituted double bond by first epimerizing (+)-sclareolide and then performing a 
stereoselective elimination. For the tetralone system 3, they applied an Ir-catalyzed 
enantioselective hydroxymethylation and cross-metathesis. In general, both routes show a 
concise approach to the polyketide motif while applying different strategies for the 
introduction of the stereocenter, but rather run through a long approach for fragment 2. We 
envisioned a robust synthetic approach for both fragments to pave the way for a more 
efficient preparation of the meroterpenoid.   
We planned the synthesis of iodide 2 employing a carbozirconation and subsequent 
iodination as the last step from alkyne 4. Polyketide 3 could be prepared starting from 6 via 
enantioselective Sharpless epoxidation followed by a stereoselective siloxy-epoxide 
rearrangement introduced by Yamamoto(Scheme 1).  
 




Scheme 1: Retrosynthetic analysis of actinoranone 1. 
2. Results and Discussion 
The synthesis of fragment 2 started with the preparation of trisubstituted 7,8-alkene 7 from 
commercially available (+)-sclareolide (5) (Scheme 2). Treatment of 5 with sulfuric acid in 
methanol caused a one-pot methanolysis of the lactone followed by elimination of the 
obtained tertiary alcohol at C8.26 The ratio of 8,9-alkene, 7,8-alkene 7, and exo-alkene was 
optimized by screening different reaction temperatures and times. After three days at 23 °C, 
a mixture of alkene-isomers (7,8, 8,9, 8,19 = 1.0:0.2:0.7) with 7,8-alkene 7 as the major 
product was obtained. Refluxing the solution for 24 h favored formation of the 
thermodynamically more stable 8,9-alkene resulting in a 1:1 ratio of alkene isomers (7,8, 
8,9).  
 
Scheme 2: Synthesis of fragment 2. 
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Reduction of the reaction time to 3 h gave the best result for the desired 7,8-alkene 7 (60% 
yield, 1.0:0.67). Other acids such as HCl, AcOH, or H3PO4 gave a similar ratio or no product at 
all, respectively. Nonetheless, the rate of the 7,8-, 8,9-, 8,19-alkene could be enhanced in 
comparison to the 1:2:0 ratio stated in literature.26 
Next, the 7,8-alkene 7 was transformed to perform a two-carbon homologation. The ester 
7 was reduced to the primary alcohol 8 which was converted into iodide 9 using Appel 
conditions in excellent yield (Scheme 2). The desired two-carbon homologation reaction to 
alkyne 4 needed some effort in terms of optimization. The usage of lithium acetylide 
ethylenediamine complex (LAEDA) in DMSO27-28 at ambient temperature gave the desired 
product 4 in a moderate yield of 42% (Table 1, entry 1). Changing the solvent to DMF (entry 
2) slightly enhanced the yield of 4, whereas usage of HMPA29 decreased the yield to 7% (entry 
3). Other methods such as the reaction with in situ generated lithium trimethylsilylacetylide30 
or Sonogashira coupling31 with trimethylsilylacetylide did not show any conversion (not 
displayed). Treatment of 9 with sodium acetylide32 in DMF improved the reaction yield to 58% 
(entry 4). Further improvement led to the reaction conditions33 displayed in Scheme 2. 
Treatment of the iodide 9 with LAEDA in a 1:1 mixture of DMSO/Et2O gave alkyne 4 in 87% 
(entry 5).  
Table 1: Two-carbon homologation of 9. 
 
Entry Conditions  Solvent t (h) 
Yielda 
(%) 
1 LAEDA (2.0 equiv) at 23 °C  DMSO 72 42 
2 LAEDA (3.0 equiv) at 50 °C DMF 16 45 
3 LAEDA (2.0 equiv) at 23 °C HMPA 18 7 
4 Na–≡ (2.0 equiv) at 0 °C DMF 2 58 
5 LAEDA (3.0 equiv) at 23 °C DMSO/Et2Ob 3 87 
a Isolated yield. b 1:1 v/v was used.  
With alkyne 4 in hand, we turned our focus to Negishi’s34-35 zirconium-catalyzed 
carboalumination-iodination sequence. This protocol is a common and useful tool in organic 
chemistry for the synthesis of trisubstituted alkenes.36-37 Application of Wipf’s protocol38 led 
to E vinyl iodide 2 in 94% yield. The control of reaction temperature and slow addition of 
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reactants were crucial to avoid protonation (by quenching the iodide), as reported by Ye and 
co-workers.15 
Taken together, the key intermediate 2 was obtained from (+)-sclareolide in five steps with 
47% overall yield. Our synthetic sequence combined the approaches of the Ye and Pastre 
group in the respect that the carbonzirconation/iodination sequence and the selective 
elimination to get 7,8-alkene 7 were applied, respectively. Thereby, we  established a 
significant improvement of the synthesis of fragment 2 (Figure 2) in comparison to the 
previously reported approaches of Ye (11%, 15 steps)15 and Pastre (3.4%, 9 steps).16  
 
 
Figure 2: Comparison of the synthetic approaches to fragment 2. 
Our approach to the tetralone fragment envisioned the installation of the benzylic 
stereocenter of the alcohol 3 by using a epoxide rearrangement introduced by Yamamoto 
under rigorous chirality transfer (see Scheme 1). Therefore, the required epoxide was 
prepared starting from the readily available allylic alcohol 6 (Scheme 3).39 A catalytic Sharpless 
epoxidation40 followed by treatment with TBSOTf permitted stereoselective preparation of 
the epoxy silyl ether required for the rearrangement in good yield and excellent enantiomeric 
excess (10, Scheme 3). At this point, we investigated the antiperiplanar migration of the vicinal 
C–C bond to benzylic position using a Yamamoto inspired rearrangement.40-43 Therefore, we 
applied the original reaction conditions using stoichiometrically amounts of the in situ formed 
aluminum-based Lewis acid MABR (methylaluminum bis-(4-bromo-2,6-di-tert-
butylphenoxide)).44-48 The originally described work-up with NaF∙H2O gave aldehyde 11 in 33% 
yield and a decreased enantiomeric excess (ee) of 60% (Table 1, entry 1). Therefore, we 
decided to screen various work-up methods to avoid undesired racemization (entries 2–6). 
Pouring the crude into diluted aqueous HCl enhanced the yield to 65%, while strongly reduced 
ee (33%) was observed (entry 2). Addition of saturated aqueous NH4Cl or H2O did not give 
better results in terms of yield and enantioselectivity (entries 3 and 4). Removal of the reaction 
solvent yielded 36% of 11 (57% ee, entry 5). The newly formed β-siloxy aldehyde proved to be 
sensitive to the applied work-up conditions. Hence, we decided to directly submit the reaction 
mixture to Wittig olefination. Direct addition of the freshly prepared Wittig reagent gave poor 
yield of 11 (entry 6). Thus, the reaction mixture was concentrated and re-dissolved in THF prior 
ylide addition. To our delight, unsaturated ester 12 was obtained in 44% yield suppressing the 
undesired racemization (entry 7). After extensive screening, we found out that addition of THF 
followed by careful removal of CH2Cl2 gave the best result. Unsaturated ester was finally 
obtained in 71% yield and 96% ee (entry 8).  
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Table 2: Optimization of the siloxy-epoxide rearrangement. 
 





NaF (6.0 equiv), H2O (8.0 equiv) 
addition, stirring at 23 °C for 
30 min, filtration over Celite® 
11 33 60 
2 Poured into diluted HCl solution, 
extraction with CH2Cl2 
11 65 33 
3 Addition of saturated NH4Cl 
solution, extraction with CH2Cl2 
11 38 7 
4 Addition of H2O (excess), 
extraction with CH2Cl2 
11 61 14 
5 Removal of CH2Cl2 under HV 11 36 57 
6c Addition to Wittig reagent 11 3 – 
7 
Removal of CH2Cl2 under HV, 
redissolved in THF and addition to 
Wittig reagent 
12 44 96 
8 
Addition of THF, removal of CH2Cl2 
under HV, addition to Wittig 
reagent 
12 71 96 
a After the described work-up, flash column chromatography (10:1 = pentane: 
Et2O) was performed. bIsolated yield. cee was not measured. 
 
The route to fragment 3 continued with the hydrogenation of the double bond of 12 using 
Pd/C (10 w%) under H2-atmosphere. The use of MeOH as solvent led to alkene reduction 
accompanied by undesired cleavage of the silyl group.49 Changing the solvent to MeCN gave 
ester 13 in 93% yield. At this point, synthesis towards the bicyclic alcohol 3 was completed 
using an approach similar to Pastre´s route.16 Thus, ester 13 was transformed into aldehyde 
14 via DIBAL-H reduction in 83% yield. Acid catalyzed cyclization using pTSA followed by 
hydrogenation employing Pd/C in MeOH (10 w%, slightly acidic) led to bicyclic alcohol 3 in 66% 
yield. 
 




Scheme 15: Synthesis of fragment 3. 
Overall, the key fragment 3 was obtained in a sequence of nine steps starting from 3,5-
dimethoxybenzaldehyde. Our route does not differ in the step count in comparison to Ye’s 
and Pastre’s but displays another synthetic approach to this bicyclic system. We improved 
Pastre’s approach by changing the way to install the stereogenic center. They used a 
hydroxymethylation route which gave good result in terms of enantioselectivity but low 
reaction yield of 51%. We used on the other side the Sharpless epoxidation and 
organoaluminum-promoted rearrangement procedure to install the stereocenter in good 
yield and enantioselectivity. Ye relied on an auxiliary approach where an oxazolidinone unit 
has to be firstly introduced and later cleaved of again. Thereby, we improved the overall yield 
to 17% (Figure 3) compared to the Ye (15%) and Pastre group (3.5%). 
 
Figure 11: Comparison of the synthetic approaches to fragment 3. 
Finally, the coupling of both fragments was performed following Ye’s15 and Pastre’s16 
procedure. Oxidation of 3 employing DMP gave aldehyde 15, which was readily added to a 
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solution of in situ lithiated vinyl iodide 2. The allylic alcohol 16 was obtained in 70% yield 
completing the formal synthesis of actinoranone (Figure 4).  
 
 
Figure 12: Completion of the formal synthesis of actinoranone 1.15 
According to Xu’s and Ye’s work,15 actinoranone 1 can be obtained in three additional steps 
inverting the configuration at C-15 under Mitsunobu conditions, performing a benzylic C–H 
oxidation using DDQ, and basic hydrolysis of the ester. 
 
3. Conclusion 
In summary, we reported a convergent formal synthesis of actinoranone 1 starting from 
commercially available (+)-sclareolide 5 and allylic alcohol 6. The synthesis of the terpenoid 
fragment was completed in five steps and 47% yield using a two-carbon homologation and a 
subsequent zirconium-catalyzed carboalumination led to bicyclic terpenoid 2. The polyketide 
fragment was obtained in nine steps with 17% overall yield. Hereby, we displayed another 
route to install the stereocenter at the benzylic position by using a catalytic Sharpless 
epoxidation which is followed by a organoaluminum-promoted epoxide rearrangement 
introduced by Yamamoto with rigorous chirality transfer. Assembling of actinoranone´s 
carbon framework could be achieved in 16 steps (11 steps LLS, 12% overall yield) offering a 
more efficient alternative to the previous works of Ye’s (26 steps, 19 steps LLS) and Pastre’s 
(20 steps, 11 steps LLS). 
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4) CONCLUSION AND OUTLOOK 
In summary, the syntheses of three natural products, (+)-vitepyrroloid A (1a), (+)-vitepyrroloid 
B (1b), and actinoranone framework (25), were successfully achieved in the course of this 
thesis. This work has demonstrated the potential of the diterpenoid (+)-sclareolide as a 
suitable building block for the synthesis of suchlike compounds. In each case, a strategic 
disconnection of the molecule of interest led to suitable fragments that were targeted by 
succinct and straightforward synthetic routes. (+)-Sclareolide, a sesquiterpene lactone and 
natural product derived from various plant sources such as Salvia sclarea, Salvia yosgadensis, 
and cigar tobacco, was identified as a readily available useful basis.[72-73] Therefore, a minimal 
amount of C─C bond formations and stereocenter introduction was necessary to obtain the 
desired compounds by employing readily available diterpene starting material. 
In more detail, the syntheses of (+)-vitepyrroloids A (1a) and B (1b) were accomplished in five 
and six steps in the longest linear sequence, respectively. 3-Bromopyrrole-2-carboxylic acid 
methyl ester (38) served as starting point for the three-step preparation of the aryl bromide 
fragment 37. The sequence included amide formation and final dehydration (81% yield in 
three steps, Scheme 15). The alkyl iodide fragment 39 was obtained from (+)-sclareolide (13) 
in a four-step route (48% yield, Scheme 15) featuring methanolysis and double bond 
formation, stereoselective epoxidation followed by reductive opening, and conclusive APPEL-
like iodination. The key step consisted of the Csp2─Csp3 cross-electrophile coupling to connect 
the two fragments. This type of coupling reaction received increasing attention and showed a 
rapid development in the last two decades. The direct coupling of two electrophiles under 
reductive conditions could be achieved avoiding Umpolung reactions and preformed 
nucleophiles that would, for instance, demand protecting group manipulations.[74-76] Despite 
these advantages, potential side reactions due to selectivity issues, reductive homocoupling, 
hydride functionalization, or catalyst deactivation are constituting the main drawbacks of this 
methodology. In addition, the rather restricted active systems are enhancing the challenge for 
a broad substrate scope and its application in natural product synthesis. However, we 
overcame this major challenge by screening a variety of catalytic systems and found that a 
reported procedure[77] using NiI2/bpy and Zn worked best for our desired coupling step with 
an initial yield of 12% for the natural product 1a. Taking inspiration from other successful 
coupling methods reported in the literature, we optimized the reaction conditions employing 
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increased temperatures and using NaI as an additive to provide an improved yield of 40%.[75] 
In the end, two equivalents of alkyl iodide 39 were required in order to achieve a successful 
coupling of the fragments with an improved yield of 57%. Proceeding from this natural 
product, (+)-vitepyrroloid B (1b) was obtained after N-alkylation in 79% yield (Scheme 15).  
 
Scheme 15: Syntheses of the natural products (+)-vitepyrroloid A (1a) and B (1b). 
These findings indicate that some competing reactions are taking place leading to a decreased 
product formation rate, which could be partially overcome by investigating the positive effect 
of the additive and an increased amount of alkyl iodide 39. Mechanistic studies carried out by 
the WEIX group[78] revealed that an initial oxidative addition of the aryl halide to Ni(0)-catalyst 
is taking place. The alkyl halide serves as a radical precursor, which then reacts in a one-
electron oxidative addition with the preformed aryl-Ni(I) complex. Based on these 
assumptions, the high amount of alkyl iodide 39 implies that the primary radical formation 
might be slow or hampered. This hypothesis is in alliance with the observation that NaI 
enhanced the reaction in the beginning. The additive favors suppression of homocoupling 
between aryl halides and thereby ensures productive cross-coupling. However, the exclusive 
addition of NaI is not enough to gain higher conversion to the desired product. Further studies 
such as identification of all by-products and NMR- or MS-assisted reaction tracking would be 
required to elucidate the rate-determining step and side reactions. Thereafter, the yield might 
be increased and in the best case, the amount of alkyl iodide needed could be reduced. Higher 
reaction temperature and reduced reaction time might also lead to further improvement. The 
literature examples also showed that the use of alkyl bromides generally led to higher product 
yields in the coupling reaction.[78] Studying the effect of different halide species is, therefore, 
another approach to increase the reaction yield. In general, a strategic investigation of the 
cross-electrophile coupling of these fragments should be envisioned. Nevertheless, the 
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application of this method led to a concise and protecting-group-free synthesis of (+)-
vitepyrroloid A (1a) and B (1b) and thus demonstrated the usefulness of this strategy in natural 
product synthesis. Although the idea of cross-electrophile coupling has been already realized, 
this thesis demonstrated one of the rare examples where this method has been applied in a 
semisynthesis along with a synthetic approach of the HODGSON group.[79] Beyond that, another 
strategy for the coupling was presented in this work: the electrochemical sp2─sp3 cross-
electrophile coupling.[80] In the first attempts, this method showed promising results with 21% 
product yield and should be further investigated to access the natural products in higher 
quantity; thus, a broader study of the biological activity should be fulfilled. So far, (+)-
vitepyrroloid A (1a) and B (1b) have only been tested against human nasopharyngeal 
carcinoma cells after their initial isolation.[55] 
The installation of a Δ8,9-alkene in (+)-sclareolide was another key step in the synthetic route 
towards the labdane diterpenoids. To obtain the alkene, (+)-sclareolide (13) was treated with 
sulfuric acid in methanol resulting in the methanolysis of the lactone and subsequent tertiary 
alcohol elimination. The ratio of Δ8,9-, Δ7,8-, and exo-alkene (42, 43, and 44) was optimized by 
increasing the reaction temperature and time, which shifted the equilibrium to the 
thermodynamic product 42 (70% yield, Scheme 16). The application of harsh conditions such 
as the reaction execution in a pressure tube at 95 °C did not result in a further shift of the 
equilibrium toward the thermodynamic product. 
 
Scheme 16: Methanolysis and elimination of the resulting tertiary alcohol starting from (+)-sclareolide (13). 
The use of other acids such as HCl, AcOH, or H3PO4 did not improve the product ratio any 
further. In a first attempt, the pure Δ7,8-alkene 43 was again exposed to the general reaction 
conditions resulting in a mixture of the isomers after three hours (Δ8,9: Δ7,8: Δ8,19 = 1:2.2:0.1). 
This finding might suggest a reaction protocol with a few iterations. Herein the reaction should 
be quenched after a certain time to isolate the Δ8,9-alkene 42 and then the remaining to Δ7,8-
alkene could be exposed again to the reaction set-up. The procedure should, hence, increase 
the overall yield by “harvesting” the desired Δ8,9-alkene 42
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which the undesired alkenes 43 and 44, are isomerized, for instance, by Pd catalysis to 42. 
Nevertheless, the improved yield of the thermodynamic product in comparison to the 
reported results (1:2 ratio of Δ8,9-:Δ7,8-alkene)[81] displays a great accomplishment. The results 
also demonstrate the possibility to control the formation of a specific alkene by varying the 
reaction conditions. 
The same conceptional strategy, consisting of methanolysis and subsequent tertiary alcohol 
elimination of (+)-sclareolide, was applied in the formal synthesis of actinoranone (9). 
However, in this case, the Δ7,8-alkene 43 was required for the formation of the desired decalin 
fragment. The best results were obtained after refluxing the reaction mixture for three hours 
giving 60% of the trisubstituted endo-alkene 43 (Scheme 16). This reaction time indicates the 
point before the equilibrium is shifted to the thermodynamic product 42 and after the kinetic 
exo-alkene product 44 is isomerized. In addition, we were able to manage the separation of 
the isomeric products, which has previously been described as particularly challenging.[81] 
Follow-up transformations gave terminal alkyne 41, which was converted to vinyl iodide 10 
via NEGISHI’s zirconium-catalyzed carboalumination/iodination sequence. Although this 
method was widely applied in organic synthesis,[82-83] the YE group encountered problems such 
as hydride functionalization using this strategy in their total synthesis of actinoranone.[64] We 
overcame these obstacles by strictly controlling the time of reagent addition and reaction 
temperature. After optimization of these key steps, we obtained the decalin fragment using a 
concise and protecting-group-free synthesis (47%, five steps, Figure 10). The results constitute 
a major improvement in the product yield with fewer steps in comparison to the synthetic 
route of YE (11%, 15 steps)[64] and PASTRE (3.4%, 9 steps).[67] 
 
Figure 13: Comparison of the synthetic approaches to fragment 10. 
The tetralone fragment was synthesized in nine steps in a similar manner to the already 
published routes. Starting from 3,5-dimethoxybenzaldehyde, the epoxy silyl ether 45 was 
obtained after enantioselective SHARPLESS epoxidation of the previously formed allylic alcohol 
40. The following organoaluminum-promoted rearrangement inspired by YAMAMOTO 
PART A: CONCLUSION AND OUTLOOK 
 
46 
rigorously transferred the preinstalled stereo information. This aluminum-based LEWIS acid 
promoted rearrangement is a common method[60, 84-85] used to obtain β-siloxy aldehydes; 
however, we encountered many problems in isolating the β-siloxy aldehyde. Major loss of 
material and erosion of enantiomeric excess were detected after application of several work-
up conditions. Since the aldehyde was unstable, it was directly converted in the following 
WITTIG reaction. In this case, no loss of stereo information was observed, and the unsaturated 
ester 46 was obtained in 71% yield (96% ee). To further improve this step, the removal of 
solvent and the addition rate to the WITTIG reagent should be rigorously controlled. The next 
steps included hydrogenation, reduction using DIBAL-H, FRIEDEL–CRAFTS cyclization, and final 
hydrogenation to obtain bicyclic alcohol 11. The last two steps were in accordance with 
PASTRE’s route. Using our approach, an increased overall yield was achieved for the polyketide 
fragment 11 as in the decalin route (17% overall yield, Figure 11). 
 
Figure 14: Comparison of the different approaches to fragment 11. 
The two fragments were finally coupled according to YE’s[64] and PASTRE’s[67] procedure to 
complete the skeleton of the natural product actinoranone (9) and thus its formal synthesis 
with 70% yield (Scheme 17).  
 
Scheme 17: Sketch of the actinoranone backbone synthesis. 
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Unfortunately, we were not able to reproduce the three final steps towards the natural 
product following YE´s procedure.[64] This should be the aim of future work. Furthermore, a 
more succinct route towards the bicyclic alcohol fragment 11 should be envisioned. The 
synthesis of the ester 46 is straightforward but the cyclization and follow-up reaction towards 
fragment 11 is rather tedious. A direct cyclization approach at the ester stage might shorten 
the synthesis and would increase the overall yield. Nevertheless, we reported herein a new 
synthetic sequence to access the natural product actinoranone, which disclosed a more 
concise strategy compared to the YE’s lengthy and PASTRE’s low-yielding approaches of the 
terpenoid fragment (five steps, 47%). Our synthetic plan combined their routes regarding 
selective elimination and vinyl iodide formation. On the other side, the polyketide fragment 
10 was obtained in the same step-count but with a higher overall yield (17% compared to 15% 
and 3.5%) in comparison to the two published routes. We hereby applied another approach 
to installing the stereocenter at the benzylic position by optimizing a known organoaluminum-
promoted epoxide rearrangement introduced by YAMAMOTO. The assembly of actinoranone’s 
framework was achieved in 16 steps (11 steps LLS, 12% overall yield) offering a more efficient 
alternative to the previously reported works. 
Overall, the presented synthetic routes of vitepyrroloids A (1a) and B (1b) and actinoranone 
skeleton 25 demonstrated the potential of (+)-sclareolide as a suitable and powerful building 
block. By varying reaction conditions, we could control the formation of the desired alkene 
after methanolysis and alcohol elimination from the sesquiterpene lactone, thus, providing a 
tool towards the synthesis of the carbon framework of different natural products starting from 
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1.1 Asymmetric α-halogenation of carbonyl compounds 
 
One of the major challenges in organic chemistry is the stereoselective carbon–halogen bond 
formation. Their importance arises from the beneficing of the obtained products as versatile 
synthetic intermediates due to the good leaving ability of the halogen atom. In particular, alkyl 
halides are key precursors for the formation of carbon–carbon bonds, ethers, amines, sulfides, 
or epoxides.[86] These properties are also useful in case of natural product synthesis where 
readily available, optically enriched, and multifunctional building blocks are beneficial. 
Additionally, halides are often introduced into pharmaceutically active compounds in 
medicinal chemistry to decrease the rate of metabolic degradation without affecting the 
existing positive pharmacological effects and therefore enhancing the therapeutic efficiency 
in comparison to their parent compounds.[87]  
For a profitable stereoselective synthesis campaign, α-haloaldehydes signify extraordinary 
starting materials due to their bifunctional nature, availability from feedstock chemicals, and 
inherent chirality.[88] The first α-haloaldehyde synthesis was already reported by SCHRÖDER in 
1871 who treated valeraldehyde with chlorine gas, which led to a racemic mixture of 
products.[86, 89] The preparation of optically pure α-haloaldehydes took almost a century, they 
were reported for the first time in the process of preparing 2-deoxy-2-fluorosugars in the 
1960s.[90] Herein the stereogenic information was transferred from the carbohydrate chiral 
pool. Introduction of chiral information by means of carbon–halogen bond formation proved 
to be an arduous challenge to overcome in the latter half of the 20th century. It is striking that 
a wide range of catalytic asymmetric carbon–carbon, carbon–heteroatom, and carbon–
hydrogen bond formations[91] are discussed in the literature; however, methods for the 
stereoselective formation of carbon–halogen bonds are much less reported. This could be 
ascribed to the common use of highly reactive molecular halides as halogen source. The 
incompatibility of these reagents with catalysis increased the demand for milder and more 
sophisticated halogenation reagents that offer greater tolerance in catalytic systems.[92] A 
milestone facing this challenge was the work of HINTERMANN and TOGNI in 2000 in which they 
reported the first catalytic asymmetric α-halogenation of carbonyl compounds using chiral 
LEWIS acid catalysis. With the use of titanium-based LEWIS acids, they successfully achieved α-
fluorination and α-chlorination of 1,3-dicarbonyl compounds 47 (Scheme 18).[93-95] 




Scheme 18: Asymmetric α-halogenation of β-ketoesters by HINTERMANN and TOGNI catalyzed by Ti(TADDOL)-based 
LEWIS acid.[93-95] 
 
A variety of enantioselective halogenation of β-ketoesters based on LEWIS acid catalysis 
followed after this milestone work.[96-98] JØRGENSEN’s method, comprising a selective α-
bromination/α-chlorination by a chiral copper complex, attracted huge attention among 
these.[99] However, the formation of optically active α-halocarbonyl compounds was solely 
restricted to 1,3-dicarbonyls to this point. LECTKA et al. then introduced the enantioselective 
α-chlorination and α-bromination of acid chlorides 49 by chiral nucleophiles derived from 
cinchona alkaloids as phase-transfer catalysts and polyhalogenated quinones as halogen 
sources after resin-supported formation of ketenes 50 (Scheme 19).[92, 100-102]  
 
Scheme 19: LECTKA’s enantioselective α-chlorination/bromination of acid chlorides.[92, 100-102] 
After the developed methods using LEWIS acids and cinchona alkaloid nucleophile, the 
introduction of new types of organocatalysts such as chiral secondary amines was the next 
important landmark in the development of asymmetric catalytic α-halogenation of carbonyl 
compounds. In 2004, not only the group of MACMILLAN[103] but also JØRGENSEN and co-
workers,[104] as well as, BARBAS and co-workers[105] independently presented the first 
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organocatalytic α-chlorination and α-fluorination of aldehydes. The α-halogenation of ketones 
52 by JØRGENSEN was also established using C2-symmetric diamine and N-chlorosuccinimide 
(NCS) in the same year (Scheme 20).[106-107] 
  
Scheme 20: JØRGENSEN’s organocatalytic α-chlorination of alkyl and cyclic ketones using NCS.[107] 
The development of the aforementioned organocatalytic approaches allowed for the scalable 
preparation of enantioenriched α-haloaldehydes, which can be employed as intermediates in 
organic and natural product synthesis since they are described as a highly versatile building.[88, 
108-113] In this regard, the BRITTON group highlighted the broad utility of enantiomerically 
enriched α-chloroaldehydes to access, for example, chiral alkaloids,[114] 
hydroxytetrahydrofurans,[115] spiroketals,[116] carbohydrates,[117] hydroxypyrrolidines,[118] and 
iminosugars.[119] A general overview of possible follow-up transformations starting from α-
haloaldehydes is depicted in Scheme 21. These products can be derived either by a stepwise 
procedure or in a one-flask approach in a stereoselective fashion. For instance, 
diastereoselective addition of organometallic reagents to α-chloroaldehydes were already 
predicted to proceed as anti by CORNFORTH’s model in 1959.[120] These additions are enabling 
access to epoxides,[121] aziridines,[122] and cyclopropanes[123] (Scheme 21, a, 54–56) in a 
stereoselective manner. Hydride reduction of the carbonyl group or reductive amination can 
lead to terminal epoxides[124-125] or aziridines (a, 54/55).[126] Nucleophilic substitutions of the 
halide by an oxygen atom (b, 57)[127] or an azide group[128] can give access to α-hydroxy or 
aminoesters (c, 58).[104] The halohydrin obtained from hydride reduction of α-haloaldehydes 
can also be converted into hydroxyamines (d, 59) by azide substitution and hydrogenolysis.[104] 
Moreover, HENRY reaction gives access to isoxazolines (e, 60),[129-131] HORNER–WADSWORTH–
EMMONS reaction yields allyl halides (f, 61),[132] STAUDINGER cycloaddition with the 
corresponding imines affords β-lactams (g, 62),[133-134] or a three-step sequence can provide 
morpholines (h, 63) or piperazines (h, 64).[135]  




Scheme 21: Stereoselective transformations of α-haloaldehydes. 
1.1.1. Organocatalytic α-chlorination of aldehydes 
 
As mentioned in the previous chapter, the landmark works of MACMILLAN[103] and JØRGENSEN[104] 
disclosed the catalytic asymmetric α-halogenation of aldehydes, thus, affording new valuable 
and versatile intermediates for organic synthesis. Especially, the utility of α-chloroaldehydes 
was elegantly demonstrated by the BRITTON group where they applied both practical 
procedures.[88, 111, 113, 117-119] MACMILLAN et al. used a chiral imidazolidinone catalyst 67 and 
hexachloro-cyclohexadiene (68) as Cl-source, whereas JØRGENSEN et al. succeeded by using L-
prolinamide or C2-symmetric catalyst 69 and NCS (70) as Cl-source (Scheme 22). 
 
Scheme 22: Organocatalytic α-chlorination of aldehydes by chiral secondary amines.[103-104] 
Both approaches paved the way to α-chloroaldehydes 66 with excellent enantiomeric excess 
(ee) and good yields, albeit expensive materials such as catalyst 69 and Cl-source 68 were 
required, and a limited reaction scope was noticed. Shortly after these two methods, the 
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MACMILLAN group established a robust enantioselective α-chlorination of aldehydes by 
organo-SOMO (single occupied molecular orbital) catalysis aiming to introduce both, a less 
expensive catalyst and Cl-source. The transformation was performed at room temperature or 
at 10 °C to achieve more enantiocontrol using LiCl as an inexpensive Cl-source and the simple 
imidazolidinone catalyst 73 (Scheme 23, exemplarily with octanal 71).[125] 
 
Scheme 23: Organo-SOMO catalysis by the MACMILLAN group with octanal.[125] 
Interestingly, the presence of a methyl group at the imidazolidinone skeleton in the catalyst 
was essential to avoid rapid decay of enantiointegrity during the course of the reaction. This 
modification suppressed the iminium-enamine equilibration after Cl-addition, which was 
observed when benzyl derivative (S)-74 was used as catalyst. These results might indicate that 
the α-chlorination is catalyst-controlled. In the MACMILLAN procedure, a so-called “linchpin” 
catalysis, the enantioenriched aldehyde was reduced afterward and directly subjected to 
base-promoted intramolecular substitution in a one-flask system to give terminal 
epoxides.[125] This concept implies that the enantioinducing step could be telescoped by 
conversion of the chiral intermediate into valuable follow-up building blocks.[136] In this 
particular case, achiral aldehydes were transformed into enantioenriched α-formyl chlorides, 
which were converted into epoxides, aziridines, or α-amino acids (see Scheme 21).[125]  
One of our group’s long-term interest comprehends the use of terpene feedstock as suitable 
building blocks in natural product synthesis.[137-139] By this, functionalization of the terpenes’ 
carbon backbone is an essential key challenge. We reported a total synthetic route to 
ripostatin B where we converted a terpene-derived aldehyde into its corresponding epoxide 
using the aforementioned organo-SOMO methodology in this context.[139] Within this study, 
problems such as diminished reaction rate and decomposition of starting material were arising 
when extended to a wider set of aldehydes. The seminal methods of MACMILLAN and JØRGENSEN 
(see Scheme 22) were also discarded due to relatively costly catalyst 69 or Cl-source 68 on an 
early step considering a scale-up process. Therefore, we sought a practical asymmetric α-
chlorination protocol with easily available reagents and reaction set-up. Our procedure 
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combined the works of MACMILLAN[125] on SOMO catalysis and JØRGENSEN´S[104] electrophilic 
chlorination, employing catalyst 73 and the inexpensive Cl-source NCS (70). The best result for 
the chlorohydrin 76 obtained after NaBH4 reduction of chlorinated test substrate (R)-
citronellal (75) is shown in Scheme 24.[108, 124] 
 
Scheme 24: Organocatalytic α-chlorination of our group.[124] 
In the context of this study, we observed that a rather substoichiometric amount of catalyst is 
needed (30 mol%). We observed the same effect when we applied this method to another 
synthesis campaign with heptandial as substrate. In this case, we could explain the high 
amount of catalyst due to the formation of an aminal resulting from the attack of the 
succinimide anion to the transient α-chloroiminium intermediate. This has stimulated further 
examination and investigation on reaction mechanism and catalyst deactivation pathway.  
 
1.1.2 Current status of organocatalytic α-chlorination mechanism 
 
In general, the oganocatalytic α-chlorination of aldehydes has been extensively discussed in 
literature.[140-141] The standard steric shielding model, outlined in cycle A (Scheme 25), is the 
generally assumed reaction mechanism applicable to MACMILLAN´S[125] and our system.[124] This 
pathway was suggested by MACMILLAN for organocatalyzed α-chlorination reactions with 
imidazolidinone catalyst systems (cycle A depicts this route with NCS as standard Cl-source 
according to the method established in our group, Scheme 25). After enamine II formation 
from aldehyde I and N-heterocyclic catalyst 73, the addition of the electrophilic chlorine 
occurs on the opposite face to the proximal bulky substituent of the catalyst forming the α-
chloroiminium ion III. Final hydrolysis releases the catalyst and the α-chloroaldehyde IV. Our 
findings of the needed high amount of catalyst in connection with the occurrence of an aminal 
as intermediate allows an extension of the standard mechanistic cycle. We hypothesized an 
off-cycle species (green, Scheme 25). 




Scheme 25: Extended catalytic cycle A with aminal V (green) following the standard steric shielding mechanism 
(black) with aminal V and downstream cycle B proposed by BLACKMOND et al. (red).[140, 142-143] 
 
The standard model of steric shielding based on the catalyst has been questioned by the 
JØRGENSEN group. For their chlorination system using 2,5-diphenylpyrrolidine 69 as catalyst and 
NCS (70) as Cl-source, they proposed that enamine intermediate i does not show any 
appreciable shielding of the reacting α-carbon center (Scheme 26). The investigation on the 
mechanism using density functional theory (DFT) revealed a reaction of the electrophilic 
chlorine source with the more nucleophilic enamine nitrogen atom leading to N-
chloroiminium ion intermediate ii (path A in Scheme 26).  
 
Scheme 26: Mechanism for the organocatalytic α-chlorination proposed by JØRGENSEN.[141] 
This proposal excluded the direct addition of Cl+ to the enamine carbon center (iii, path B in 
Scheme 26) and rather envisioned a 1,3-sigmatropic chlorine shift forming thermodynamically 
favored iii via intermediate ii when a pyrrolidine catalyst is used.[141] 
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The group of JØRGENSEN has investigated the reaction mechanism for the α-chlorination using 
1H NMR studies to further elucidate product-limiting steps. They found that an aminal 
structure resulting from the succinimide anion addition to the formed α-chloroiminium ion iii 
under anhydrous conditions might have led to catalyst deactivation.[141] As indicated in the 
previous chapter, our group also detected these kind of intermediates under standard 
reaction conditions (see compound V in Scheme 25 as exemplary aminal). In the same context, 
BLACKMOND and co-workers investigated the accuracy of their proposed concept of “CURTIN–
HAMMOND paradigm” on the organocatalytic α-chlorination of isovaleraldehyde (77) with NCS 
(70) and the JØRGENSEN–HAYASHI catalyst. Just as the JØRGENSEN group, they were able to detect 
aminal 78 (Scheme 27) in 1H NMR-studies but did not succeed in its isolation.[140, 142-143]  
 
Scheme 27: Mechanistic investigation by the BLACKMOND group with isovaleraldehyde (77) and NCS (70).[140] 
Based on these findings, they proposed a secondary stereodetermining catalytic cycle with 
aminal V participating (exemplary depicted with imidazolidinone catalyst 73 and NCS (70), 
Scheme 25, red pathway) rather than being an off-cycle intermediate. In their opinion, Z-
chloroenamine VI is formed after E2 elimination of succinimide from aminal V. The cycle 
would be completed by diastereoselective protonation to α-chloroiminium ion III which would 
then be hydrolyzed signifying the downstream to the primary cycle (Scheme 25). It is 
important to note that in accordance with the observed stereoinduction, the protonation in 
this scenario has to occur from the opposite face of the enamine compared to the 
aforementioned addition of the electrophilic chlorine. Nevertheless, the BLACKMOND group was 
not able to prove this diastereoselective protonation mechanism.[140] The effect of aminal V 
on the organocatalyzed reaction is not yet clarified. The isolation of this crucial adduct would 
be essential for an exhaustive investigation of the organocatalytic α-chlorination of aldehydes 
and allow the elucidation of its role in the catalytic cycle.   
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2) SCIENTIFIC GOALS 
Despite a broad substrate scope and excellent enantio- and diastereoselectivity, the 
organocatalytic α-chlorination method established in our group showed some weaknesses 
with respect to catalyst loading (30 mol%). The observation of an aminal as by-product might 
explain the high amount of organocatalyst needed. These preliminary findings raised the 
question of the role of this aminal. Is it inevitably formed in a secondary catalytic cycle and 
thereby responsible for the enantioinduction of the reaction as suggested by the BLACKMOND 
group (cycle B, Scheme 25)? Or is it an off-cycle intermediate which lies in equilibrium with 
the α-chloroiminium ion and as a consequence suppresses the turnover of the catalyst from 
cycle A? These compelling questions should be answered by extensive 1H NMR- and kinetic 
isotope effect studies of the envisioned isolable aminal compounds. 
Furthermore, our early observations also prompted the question if the formation of the 
aminal could be avoided. This would then cause a higher catalyst turnover with probably 
beneficial effects on product yield and catalyst loading. At the outset, we chose 
hydrocinnamaldehyde (88) for its reliable UV-profile as a test substrate to investigate the 
organocatalytic α-chlorination. For this purpose, different imidazolidinone catalysts with 
varied substituent patterns (80–83), a large number of established and novel Cl-sources (84–
87), the solvent influence, and the impact of additives such as BRØNSTED acids and LEWIS 
acids/bases was planned to be examined (Scheme 28).  
Therefore, the objective of this work was the optimization of the reaction conditions for the 
organocatalytic α-chlorination of aldehydes with a broad substrate scope and excellent yields 
and enantiomeric excess. In this context, we sought to combine GC-MS measurements and 
NMR-studies for a deeper understanding of the reaction profile. These findings should give us 
the opportunity to adjust the reaction conditions and thus to enhance the aminal 
accumulation or even suppress its formation. Moreover, we were aiming for the isolation of 
the observed aminal with hydrocinnamaldehyde (89) to further study its stability and decay in 
terms of stereoselectivity (Scheme 28). Addition of H2O and/or acids might provide 
information about the reactivity of the aminal. The reaction of this intermediate under 
deuterium conditions of the reaction set-up should give further indications of its 
decomposition and hence might elucidate the aminal role as either an off-cycle intermediate 
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or as part of a secondary stereodetermining catalytic cycle. With this study, we were seeking 
to rationalize the reaction mechanism in detail and thereby prevent accumulation or suppress 
the aminal formation to eventually optimize the organocatalytic α-chlorination of aldehydes.  
 
Scheme 28: Some possible imidazolidinone catalysts and Cl-sources stated for the optimization of the 
organocatalytic α-chlorination and formation of the aminal and its possible decay. 
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3.1 Mechanistic Studies on the Organocatalytic α-Chlorination of Aldehydes: The Role and 
Nature of Off-Cycle Intermediates 
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Abstract: 
In this mechanistic study, the isolation and characterization of aminal intermediates in the 
organocatalytic α-chlorination of aldehydes is reported. These species are stable, covalently 
linked ternary adducts of the substrate, the catalyst, and the chlorinating agent. NMR-assisted 
kinetic studies and isotopic labeling experiments with the isolated intermediates did not 
support its involvement in downstream stereoselective processes as proposed by BLACKMOND 
et al. By tuning the reactivity of the chlorinating reagent, we were able to suppress the 
accumulation of rate-limiting off-cycle intermediates. As a result, an efficient and highly 
enantioselective catalytic system with a broad functional group tolerance was developed. 
 
Authors’ contribution: 
I developed the general concept to analyze the intermediate formation and started the project 
by elaborating the model reaction with hydrocinnamaldehyde, NCS, and MACMILLAN’s 
imidazolidinone catalyst. In this context, I was able to isolate single crystals of the 
intermediate derived from octanal, pentanal, and hydrocinnamaldehyde. I explored the 
impact of several additives such as LEWIS-acids, BRØNSTED-acids, etc. and different solvents on 
the reaction outcome and aminal formation and suppression. Therefore, I developed a 
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feasible GC-MS method which was further used in the studies of the first author. In addition 
to that, preliminary NMR-studies following the reaction progress and the decomposition of 
aminal intermediate were conducted by me. Moreover, I was varying the alkyl-group at the 
C5 position of the imidazolidinone catalyst and screened several chlorine sources, mostly 
based on the structure of hydantoin, to enhance the α-chlorination of hydrocinnamaldehyde. 
Based on this exploratory work, the first author further pursued the study and investigated 
the impact of electron-deficient chlorine sources and imidazolidinone catalysts with variation 
at the C2 position. I assisted in the preparation of the manuscript, which was written by the 
first and corresponding author. 
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4) CONCLUSION AND OUTLOOK 
The previous article showed our mechanistic study on the organocatalytic α-chlorination of 
aldehydes. During this investigation, we were able to isolate and fully characterize aminal 
intermediates consisting of the substrate, the organocatalyst, and the chlorinating agent. The 
α-chlorination of hydrocinnamaldehyde (88) using NCS (70) and imidazolidinone catalyst 73 
served as a model reaction for a deeper investigation on the role of this ternary species. Based 
on 1H NMR-assisted kinetic studies and isotopic labelling experiments the mechanism was 
finally elucidated.  
The starting point of the study was the recognition of the high catalyst loading needed to 
pursue the organocatalytic α-chlorination of aldehydes in our previously developed 
method.[124] By analyzing the reaction outcome, we identified an aminal intermediate 
consuming the catalyst. Similar intermediates formed during the α-chlorination were already 
reported by others.[140-141] BLACKMOND et al. investigated the α-chlorination of aldehydes using 
JØRGENSEN-HAJASHI-catalyst and identified aminal intermediates in low-temperature 1H NMR 
experiments. However, they were not able to isolate such species and concluded that the 
intermediates were part of a secondary catalytic cycle. In their so-called CURTIN-HAMMET 
paradigm they claimed that the observed enantioselectivity arose from the relative 
stability/reactivity of the intermediates downstream to the primary cycle (Scheme 29, red 
pathway). In addition, BLACKMOND suggested that this mechanistic concept may present a 
general phenomenon observed for amine catalysts lacking acidic/directing protons.[140, 142-143]  
With the isolation of the aminal intermediate of hydrocinnamaldehyde 89, we were in the 
position to elucidate its role in the mechanistic cycle. We found that the choice of chlorine 
source had a major impact on reaction rate and intermediate accumulation. Electron-rich 
counterions caused a higher amount of aminal formation whereas electron-deficient 
counterions increased the reactivity towards the product. A 1H NMR study of the model 
system using imidazolidinone catalyst 73, hydrocinnamaldehyde (88), and 
tetramethylsuccinimide (85) or N-chloronitrophthalimide (84) as chlorine sources revealed 
rapid decomposition of the aminal when 84 was employed. The weakened N–C bond in 
aminals of type V facilitates the decay of the intermediate. The result marks the good leaving 
group ability of the nitrophthalimide anion. The relative amount of the ternary intermediate 
can thus be controlled by modulating the reactivity of the chlorine source.  




Scheme 29: Extended catalytic cycle A following the standard steric shielding mechanism (black) and 
downstream cycle B proposed by BLACKMOND (red).[140, 142-143] 
 
The kinetic profile also showed that the rate of product formation was not depending on the 
decomposition of V in a secondary catalytic cycle as suggested by BLACKMOND.[140, 142-143]  
Additionally, the decay of the aminal 89 was investigated by subjecting the intermediate to 
the general reaction conditions in the presence of deuterated solvent and acid additives. 
Product formation was slow but after one hour no deuterium was incorporated in the α-
position of the aldehyde. This finding is in contrast to the proposed mechanism of the 
BLACKMOND group. They assumed that after chlorine addition, E2 elimination is taking place 
leading to the Z-chloroenamine VI (red pathway, Scheme 29). Diastereoselective protonation 
would then lead to the α-chloroiminium ion III of the primary cycle.[140, 142-143] Under these 
circumstances, deuterium incorporation should be detected after decomposition of the 
intermediate. After 19 h most of the intermediate had been decayed and 1H NMR of the 
product mixture displayed partial deuterium incorporation probably due to racemization of 
the product as underlined by the drop of enantiomeric excess. After 66 h, the α-
chlorohydrocinnamaldehyde (90) was nearly racemic. 
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All these observations support a classical mechanistic proposal where the enamine 
chlorination is the stereo-determining step. Moreover, we pointed out that the off-cycle 
aminal intermediate V can become rate-limiting by deactivating the catalyst, this could be 
overcome by the choice of chlorinating agent. The general application of this mechanistic 
concept remains to be surveyed. In this regard, our model system should be applied to other 
organocatalysts such as the JØRGENSEN–HAJASHI-catalyst, which has been already used by the 
BLACKMOND group. Thus, we could directly compare both reactions and intermediate formation 
to give a final proof for an off-cycle intermediate. Moreover, the formation of additional 
adducts should be investigated in more detail. It was found, for instance, that additives can 
affect the reaction. Optimal results were obtained when a 1:1:2 ratio of catalyst:TFA:AcOH 
was used. This observation indicates that acetic acid might play an additional role beyond 
being a proton source. Short-lived adducts with iminium intermediates could be one possible 
explanation. It would be interesting to investigate the exact role of these additives and their 
impact on the stability of the aminal intermediate. Therefore, an intensive mass spectrometry 
study could be conducted to identify additional adducts. In addition, 1H NMR-assisted kinetic 
studies at low-temperature, e.g., at reaction temperature itself (─30 °C) or even lower (─78 °C) 
could be performed to gain further insight into the additive impact and finally establish a fully 
corrected mechanistic catalytic cycle. 
With a deeper understanding of the α-chlorination of aldehydes, we were able to improve the 
previous reaction conditions.[124] Intensive screening of imidazolidinone catalysts with altered 
alkyl rests at C2 and C5 position, chlorine sources, solvents, and different acids led to the 
optimal conditions shown in Scheme 30. 
 
Scheme 30: Newly developed organocatalytic α-chlorination of hydrocinnamaldehyde (88). 
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We thereby reduced the catalyst loading from 30 to 5 mol%. In general, the utility of the 
catalytic system was explored for the α-chlorination of a broad and diverse set of aldehydes. 
The reaction showed good functional group tolerance (e.g., for Boc-protected primary amine, 
aryl, alkenyl, and alkynyl side chains) and excellent enantio- and diastereoselectivity (96–99% 
ee). In the case of (S)-citronellal, an allylic chlorination was taking place causing a major drop 
in the product yield. A slow addition of chlorinating agent 84 was crucial to suppress the 
undesired side reaction with the electron-rich double bond. Nevertheless, this finding could 
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All reactions sensitive to moisture and/or air were performed under an argon atmosphere 
using Schlenk techniques. Reagents and solvents were obtained from commercial sources and 
used as received unless otherwise noted. Anhydrous solvents (THF, CH2Cl2, Et2O, PhMe) were 
purified using the solvent purification system MB-SPS-800 (Braun). The solvents (EtOAc, Et2O, 
n-pentane) used for column chromatography and work up were purified from commercially 
available technical grade solvents by distillation under reduced pressure. Nuclear magnetic 
resonance spectra (1H NMR, 13C NMR) were recorded at the following frequencies: 1H NMR at 
400, 500, and 700 MHz, 13C NMR at 100, 125, and 175 MHz with solvent resonance as the 
internal standard (1H NMR: CDCl3 at 7.26 ppm, 13C NMR: CDCl3 at 77.0 ppm). 1H NMR data are 
reported as follows: chemical shift, multiplicity (s = singlet, brs = broad singlet, d = doublet, dd 
= doublet of doublet, t = triplet, m = multiplet), coupling constant (Hz), and integration. High 
resolution mass spectra were measured with a TOF mass spectrometer. TLC visualization was 
accomplished using UV light and/or staining in a Cer(IV)-sulfate solution (5.0 g 
phosphomolybdic acid, 16 mL conc. H2SO4, 200 mL H2O, 4.0 g cerium(IV) sulfate) or acidic p-
anisaldehyde solution (450 mL EtOH, 25 mL anisaldehyde, 25 mL conc. H2SO4, 8 mL AcOH) and 
subsequent charring. Yields refer to isolated yields after flash column chromatography.  
 
Synthesis of Methyl 2-((1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-
octahydronaphthalen-1-yl)acetate (7)1-2 
(3aR)-(+)-Sclareolide 5 (1.00 g, 4.00 mmol) was dissolved in MeOH (19 mL) and then treated 
with conc. H2SO4 (0.7 mL). After refluxing for 3 h, MeOH was distilled off and the residue 
dissolved in Et2O (100 mL), washed with H2O (2 x 50 mL), saturated aqueous NaHCO3 solution 
(2 x 50 mL) and brine (20 mL). The organic phase was dried over anhydrous MgSO4 and 
concentrated under reduced pressure. The crude alkenes were separated by column 
chromatography (n-pentane/Et2O = 120:1 to 80:1) giving Δ7,8-7 (636 mg, 2.4 mmol, 60%) and 
Δ8,9-7 (424 mg, 1.60 mmol, 40%) alkenes as colorless oils. 
7: Rf = 0.46 (n-pentane/Et2O = 40:1); 1H (500 MHz, CDCl3): δ = 5.47 – 5.39 (m, 1H), 3.68 (s, 
3H), 2.49 (d, J = 9.5 Hz, 1H), 2.42 – 2.35 (m, 1H), 2.17 (dd, J = 16.5, 9.7 Hz, 1H), 2.04 – 1.95 (m, 
1H), 1.84 (dddt, J = 17.5, 12.0, 4.5, 2.4 Hz, 1H), 1.75 – 1.65 (m, 1H), 1.56 – 1.53 (m, 3H), 1.53 – 
1.37 (m, 3H), 1.28 (dd, J = 12.2, 4.7 Hz, 1H), 1.18 (td, J = 13.1, 3.6 Hz, 1H), 1.09 (td, J = 13.0, 3.9 
Hz, 1H), 0.88 (s, 3H), 0.86 (s, 3H), 0.75 (s, 3H) ppm; 13C  (125 MHz, CDCl3): δ = 175.5, 133.8, 







Synthesis of 2-((1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6, 7,8,8a-octahydronaphthalen-1-
yl)ethan-1-ol (8) 
To a suspension of LiAlH4 (0.230 g, 6.05 mmol, 1.5 equiv) in anhydrous Et2O (20 mL), a 
solution of ester 7 (1.07 g, 4.04 mmol, 1.0 equiv) in anhydrous Et2O (40 mL) was added slowly 
at 0 °C. The mixture was stirred for 1 h before it was quenched by the addition of aqueous HCl 
(1 M; 50 mL). Afterwards, the mixture was extracted with Et2O (4 x 50 mL) and the combined 
organic layers were washed with saturated aqueous NaHCO3 (50 mL), dried over anhydrous 
MgSO4 and concentrated under reduced pressure. After purification by column 
chromatography (n-pentane/EtOAc = 5:1), alcohol 8 (0.954 g, 4.04 mmol, quant.) was 
obtained as colorless oil. 
8: Rf = 0.39 (n-pentane/EtOAc = 5:1); 1H (400 MHz, CDCl3): δ = 5.41 (brs, 1H), 3.78 (dt, J =  
9.5, 5.2 Hz, 1H), 3.66–3.47 (m, 1H), 2.04–1.91 (m, 1H), 1.92–1.78 (m, 1H), 1.72 (dd, J = 14.2, 
7.2 Hz, 2H), 1.66 (s, 3H), 1.66–1.64 (m, 1H), 1.57–1.45 (m, 4H), 1.40 (d, J = 13.9 Hz, 1H), 1.18 
(dd, J = 11.9, 5.1 Hz, 1H), 1.13 (dd, J = 13.1, 3.9 Hz, 1H), 0.95 (dt, J = 13.1, 3.9 Hz, 1H), 0.87 (s, 
3H), 0.85 (s, 3H), 0.76 (s, 3H) ppm; 13C (100 MHz, CDCl3): δ = 134.7, 122.8, 64.5, 50.8, 50.2, 
42.4, 39.3, 36.6, 32.3, 33.1, 30.6, 23.9, 22.2, 22.0, 18.9, 13.7 ppm. 
 
Synthesis of (4aS,5S,8aS)-5-(2-iodoethyl)-1,1,4a,6-tetrame- thyl-1,2,3,4,4a,5,8,8a-
octahydronaphthalene (9) 
To a solution of alcohol 8 (500 mg, 2.12 mmol, 1.0 equiv) in anhydrous THF (35 mL), PPh3 
(666 mg, 2.54 mmol, 1.2 equiv), imidazole (288 mg, 4.23 mmol, 2.0 equiv) and I2 (644 mg, 
2.54 mmol, 1.2 equiv) were subsequently added and the mixture was stirred for 2 h at 23 °C. 
The reaction was quenched by the addition of saturated aqueous Na2S2O3 (50 mL) and 
extracted with Et2O (3 x 50 mL). The combined organic phases were dried over anhydrous 
MgSO4 and concentrated under reduced pressure. The crude product was purified by column 
chromatography (n-pentane) giving alkyl iodide 9 (693 mg, 2.00 mmol, 95%) as colorless oil. 
9: Rf = 0.98 (n-pentane); 1H (400 MHz, CDCl3): δ = 5.42 (brs, 1H), 3.38 (ddd, J = 10.3, 9.4, 4.7 
Hz, 1H), 3.14 (td, J = 9.4, 7.5 Hz, 1H), 2.05 (dddd, J = 14.7, 10.3, 7.5, 1.8 Hz, 1H), 2.01 – 1.94 (m, 
1H), 1.89 – 1.72 (m, 3H), 1.67 (s, 3H), 1.65 – 1.60 (m, 1H), 1.56 – 1.51 (m, 1H), 1.47 (tq, J = 10.2, 
3.4 Hz, 1H), 1.41 (dtd, J = 13.1, 3.2, 1.7 Hz, 1H), 1.19 (dd, J = 12.0, 4.9 Hz, 1H), 1.15 (dd, J = 13.2, 
3.9 Hz, 1H), 1.04 (td, J = 13.1, 4.1 Hz, 1H), 0.87 (s, 3H), 0.85 (s, 3H), 0.74 (s, 3H) ppm; 13C 
(100 MHz, CDCl3): δ = 133.7, 123.4, 56.6, 50.1, 42.3, 39.3, 36.8, 33.3, 33.1, 32.7, 23.9, 22.2, 








octahydronaphthalene (4)  
To a suspension of LAEDA (40.0 mg, 0.434 mmol, 1.5 equiv) in anhydrous DMSO/Et2O (1:1 
v/v; 0.6 mL), was added a solution of iodide 9 (100 mg, 0.289 mmol, 1.0 equiv) in anhydrous 
Et2O (0.3 mL) at 0 °C. The reaction was stirred for 1 h and then another portion of LAEDA 
(40.0 mg, 0.434 mmol, 1.5 equiv) was added. After 3 h the reaction was quenched by the 
addition of H2O (2.0 mL) and extracted with Et2O (3 x 30 mL). The combined organic phases 
were washed with H2O (2 x 10 mL), dried over anhydrous MgSO4, and concentrated under 
reduced pressure. The crude product was purified by column chromatography (n-pentane) 
giving the alkyne 4 (61.7 mmol, 0.252 mmol, 87%) as colorless oil. 
4: Rf = 0.76 (n-pentane); 1H (500 MHz, CDCl3): δ = 5.41 (brs, 1H), 2.37 (dddd, J = 16.7, 9.1, 
5.0, 2.6 Hz, 1H), 2.18 (dtd, J = 16.7, 8.3, 2.6 Hz, 1H), 2.02 – 1.97 (m, 1H), 1.96 (t, J = 2.6 Hz, 1H), 
1.89 – 1.83 (m, 2H), 1.76 – 1.70 (m, 2H), 1.68 (s, 3H), 1.59 – 1.48 (m, 1H), 1.48 – 1.37 (m, 3H), 
1.22 – 1.17 (m, 1H), 1.15 (dd, J = 13.1, 3.8 Hz, 1H), 1.01 (td, J = 13.1, 3.8 Hz, 1H), 0.87 (s, 3H), 
0.85 (s, 3H), 0.75 (s, 3H) ppm; 13C (125 MHz, CDCl3): δ = 134.7, 122.9, 100.1, 85.0, 68.4, 53.8, 




To a solution of Cp2ZrCl2 (24.0 mg, 0.0820 mmol, 0.5 equiv) in anhydrous CH2Cl2 (6.0 mL), 
Me3Al (2 M in PhMe; 0.24 mL, 0.489 mmol, 3.0 equiv) was added slowly at –30 °C. The pale-
yellow mixture was stirred for 30 min at 23 °C and cooled to            –30 °C again. At this point, 
H2O (4.40 µL, 0.245 mmol, 1.5 equiv) was added and the mixture stirred for additional 30 min, 
and then a solution of alkyne 4 (40.0 mg, 0.163 mmol, 1.0 equiv) in anhydrous CH2Cl2 (0.30 mL) 
was added. After 1 h, I2 (54.0 mg, 2.12 mmol, 1.3 equiv) dissolved in anhydrous THF (0.60 mL) 
was added and the yellow solution was stirred for 4 h at 0 °C. The reaction was quenched with 
saturated aqueous NaHCO3 (10 mL) followed by extraction with n-pentane (3 x 30 mL). The 
combined organic phases were washed with brine (20 mL), dried over anhydrous MgSO4, and 
concentrated under reduced pressure. The crude product was purified by column 
chromatography (n-pentane) yielding vinyl iodide 2 (44.0 mg, 0.154 mmol, 94%) as colorless 
solid.  
2: Rf = 0.94 (n-pentane); 1H (500 MHz, CDCl3): δ = 5.89 (q, J = 1.1 Hz, 1H), 5.40 (brs, 1H), 2.46 
– 2.33 (m, 1H), 2.16 (dddd, J = 13.7, 10.3, 6.2, 0.8 Hz, 1H), 2.00 – 1.93 (m, 1H), 1.89 – 1.86 (m, 
1H), 1.85 (d, J = 1.1 Hz, 3H), 1.83 – 1.78 (m, 1H), 1.68 (brs, 3H), 1.62 – 1.47 (m, 3H), 1.47 – 1.38 
(m, 2H), 1.34 – 1.26 (m, 1H), 1.20 – 1.12 (m, 2H), 0.93 (td, J = 13.1, 3.9 Hz, 1H), 0.87 (s, 3H), 
0.85 (s, 3H), 0.75 (s, 3H) ppm; 13C (125 MHz, CDCl3): δ = 148.7, 135.0, 122.8, 75.0, 54.4, 50.3, 





Synthesis of (E)-3-(3´,5´-dimethoxyphenyl)prop-2-en-1-ol (6)4-5 
Triethyl phosphonoacetate (6.05 mL, 14.1 mmol, 1.8 equiv) was added to a suspension of 
NaH (60 w% mineral oil; 0.580 g, 24.0 mmol, 1.8 equiv) in anhydrous THF (71 mL) at 0 °C. The 
suspension cleared after stirring for 30 min, and then a solution of the 3,5-
dimethoxybenzaldehyde (2.00 g, 12.0 mmol, 1.0 equiv) in anhydrous THF (4.0 mL) was added. 
Stirring was continued for additional 16 h during gradual warming to 23 °C. The mixture was 
then quenched with saturated aqueous NH4Cl (20 mL) and extracted with Et2O (4 x 50 mL). 
The combined organic phases were dried over anhydrous MgSO4 and concentrated under 
reduced pressure. The obtained crude ester was dissolved in anhydrous CH2Cl2 (50 mL) and 
DIBAL-H (1 M in CH2Cl2; 36.0 mL, 36.1 mmol, 3.0 equiv) was slowly added at 0 °C. The reaction 
mixture was stirred for 1 h and then quenched by careful addition of aqueous HCl (1 M; 
30 mL). The mixture was stirred for 30 min and then extracted with Et2O (4 x 50 mL), dried 
over anhydrous MgSO4, and concentrated under reduced pressure. The crude product was 
purified by column chromatography (Et2O/n- pentane = 2:1) giving allylic alcohol 6 (2.01 g, 
10.4 mmol, 86%) as colorless oil. 
6: Rf = 0.66 (n-pentane/Et2O = 1:3); 1H (500 MHz, CDCl3): δ = 6.56 – 6.55 (m, 1H), 6.54 (d, J 
= 2.3 Hz, 1H), 6.53 – 6.51 (m, 1H), 6.38 – 6.36 (m, 1H), 6.34 (dd, J = 15.9, 5.7 Hz, 1H), 4.63 (brs, 
1H), 4.31 (d, J = 5.6 Hz, 2H), 3.79 (s, 6H) ppm; 13C (125 MHz, CDCl3): δ = 161.0 (2C), 138.9, 
131.1, 129.2, 104.7 (2C), 100.0, 63.7, 55.4 (2C) ppm. 
 
Synthesis of tert-butyl(((2R,3R)-3-(3´,5´-dimethoxyphenyl) oxiran-2-yl)methoxy)dimethylsilane 
(10)6 
To a suspension of (+)-DET (0.240 mL, 1.41 mmol, 0.18 equiv) and powdered (or grinded) 
4 Å MS in anhydrous CH2Cl2 (25 mL), Ti(OiPr)4 (0.350 mL, 1.17 mmol, 0.15 equiv) was added at 
‒20 °C. The mixture was stirred for 30 min and then tBuOOH (5.5 M in decane; 2.85 mL, 15.7 
mmol, 2.0 equiv,) was added. After stirring for additional 30 min at ‒20 °C, a solution of allylic 
alcohol 6 (1.52 g, 7.83 mmol, 1.0 equiv) in anhydrous CH2Cl2 (3.5 mL) was added. The reaction 
mixture was stirred for 2 h at ‒20 °C and then quenched by the addition of aqueous NaOH 
(10% w/w; 10 mL) and brine (10 mL). The mixture was filtered through a pad of Celite and the 
filtrate was then extracted with CH2Cl2 (3 x 50 mL). The combined organic phases were dried 
over anhydrous MgSO4 and concentrated under reduced pressure. The obtained crude 
epoxide was dissolved in anhydrous CH2Cl2 (77 mL) and treated with 2,6-lutidine (1.09 mL, 
9.40 mmol, 1.2 equiv) and TBSOTf (1.98 mL, 8.61 mmol, 1.1 equiv) at 0 °C. The solution was 
stirred for 2 h at this temperature before quenching with saturated aqueous NaHCO3 (30 mL) 
and extracted with CH2Cl2 (3 x 50 mL). The combined organic phases were dried with 
anhydrous MgSO4 and concentrated under reduced pressure. After purification by column 
chromatography (n-pentane/Et2O = 11:1), TBS-protected epoxide 10 (2.03 g, 6.26 mmol, 80%, 




10: Rf = 0.74 (n-pentane/Et2O = 8:1); [α]D25 = ‒28.7 (CHCl3, c = 1.0); IR:  ṽ = 833, 1152, 1252, 
1347, 1461, 1470, 1597, 2360, 1856, 2929, 2953 cm-1; 1H (500 MHz, CDCl3): δ = 6.44 (d, J = 
2.3 Hz, 2H), 6.39 (t, J = 2.3 Hz, 1H), 3.96 (dd, J = 12.1, 3.0 Hz, 1H), 3.83 – 3.79 (m, 1H), 3.78 (s, 
6H), 3.76 (d, J = 2.1 Hz, 1H), 3.12 – 3.07 (m, 1H), 0.92 (s, 9H), 0.11 (s, 3H), 0.10 (s, 3H) ppm; 13C 
(125 MHz, CDCl3): δ = 161.2 (2C), 140.0, 103.5 (2C), 100.5, 63.0, 62.7, 56.0, 55.5 (2C), 26.0 (3C), 
18.6, ‒5.1 (2C) ppm; HRMS (ESI): [M+Na]+ calculated for C17H28O4SiNa+: 347.1649, found: 
347.1640; [M+K]+ calculated for C17H28O4SiK+:  363.1389, found: 363.1391. 
 
Synthesis of ethyl (S,E)-5-((tert-butyldimethylsilyl)oxy)-4-(3´,5´-dimethoxyphenyl)pent-2-
enoate (12)6 
4-Bromo-2,6-di-tert-butylphenol (703 mg, 2.46 mmol, 4.0 equiv) was dissolved in 
anhydrous CH2Cl2 (14 mL) and the yellow solution was degassed (freeze-pump-thaw; three 
cycles). Subsequent addition of Me3Al (2 M in PhMe; 0.62 mL, 1.23 mmol, 2.0 equiv,) gave a 
colorless solution. Stirring was continued for 1 h till the gas development has ceased. After 
cooling to ‒78 °C, a solution of epoxide 10 (200 mg, 0.616 mmol, 1.0 equiv) in CH2Cl2 (1.5 mL) 
was added to give a bright yellow solution. After 15 min stirring, anhydrous THF (3.0 mL) was 
added to the mixture and CH2Cl2 was carefully removed HV during warming to 23 °C. The 
resulting solution was then added to a suspension of the Wittig reagent (845 mg, 1.85 mmol, 
3.0 equiv) and KOtBu (200 mg, 1.79 mmol, 2.9 equiv) in anhydrous THF (8.0 mL) which was 
previously reacted for 30 min at 0 °C. The reaction mixture was stirred for additional 4 h at 
0 °C and quenched with saturated aqueous NH4Cl (20 mL). The mixture was extracted with 
Et2O (4 x 50 mL), the combined organic phases were dried over anhydrous MgSO4 and 
concentrated under reduced pressure. The crude product was purified by column 
chromatography (n-pentane/Et2O = 11:1) yielding ester 12 as pale-yellow oil (173 mg, 
0.437 mmol, 71%, 96% ee). 
12: Rf = 0.45 (n-pentane/Et2O = 8:1); [α]D25 = +12.8 (CHCl3, c = 1.4); IR:  ṽ = 833, 1152, 1428, 
1461, 1594, 1717, 2856, 2929, 2953 cm-1; 1H (500 MHz, CDCl3): δ = 7.15 (dd, J = 15.8, 7.3 Hz, 
1H), 6.39 – 6.26 (m, 3H), 5.85 (dd, J = 15.8, 1.4 Hz, 1H), 4.18 (q, J = 7.1 Hz, 2H), 3.85 (d, J = 
6.7 Hz, 2H), 3.78 (s, 6H), 3.54 (q, J = 6.7 Hz, 1H), 1.27 (t, J = 7.1 Hz, 3H), 0.86 (s, 9H), 0.01 (s, 
3H), ‒0.01 (s, 3H) ppm; 13C (125 MHz, CDCl3): δ = 166.4, 160.8 (2C), 148.4, 142.0, 122.5, 106.4 
(2C), 98.7, 66.2, 60.1, 55.2 (2C), 51.2, 25.7 (3C), 18.1, 14.1, ‒5.6 (2C) ppm; HRMS (ESI): [M+H]+ 
calculated for C21H34O5SiH+: 395.2249, found: 395.2230; [M+Na]+ calculated for C21H34O5SiNa+:  








Synthesis of ethyl (S)-5-((tert-butyldimethylsilyl)oxy)-4-(3´,5´-dimethoxyphenyl)pentanoate 
(13) 
A mixture of alkene 12 (173 mg, 0.437 mmol, 1.0 equiv) and Pd/C (17.5 mg, 40 mg/mmol, 
10% w/w) in MeCN (2.0 mL) was stirred under H2 atmosphere for 16 h at 23 °C. The mixture 
was filtered through a pad of Celite and the filter cake washed with EtOAc. The filtrate was 
concentrated under reduced pressure and the residue purified by column chromatography (n-
pentane/Et2O = 9:1) giving ester 13 (161 mg, 0.406, 93%) as pale-yellow oil. 
13: Rf = 0.44 (n-pentane/Et2O = 8:1); [α]D26 = +8.15 (CHCl3, c = 0.75); IR:  ṽ = 835, 1154, 1204, 
1429, 1462, 1595, 1733, 2856, 2930, 2953 cm-1; 1H (500 MHz, CDCl3): δ = 6.34 (d, J = 2.2 Hz, 
2H), 6.32 (t, J = 2.6 Hz, 1H), 4.08 (qd, J = 7.1, 1.0 Hz, 2H), 3.77 (s, 6H), 3.73 – 3.63 (m, 2H), 2.71 
– 2.62 (m, 1H), 2.24 – 2.15 (m, 3H), 1.87 – 1.79 (m, 1H), 1.22 (t, J = 7.1 Hz, 3H), 0.86 (s, 9H), ‒
0.01 (s, 3H), ‒0.03 (s, 3H) ppm; 13C (125 MHz, CDCl3): δ = 173.8, 160.9 (2C), 144.8, 106.4 (2C), 
98.5, 67.9, 60.3, 55.4 (2C), 48.5, 32.5, 27.3, 26.0 (3C), 18.4, 14.4, ‒5.3 (2C) ppm; HRMS (ESI): 
[M+Na]+ calculated for C21H36O5SiNa+: 419.2224, found: 419.2218; [M+K]+ calculated for 
C21H36O5SiK+: 435.1964, found: 435.1949. 
 
Synthesis of (S)-5-((tert-butyldimethylsilyl)oxy)-4-(3´,5´-dimethoxyphenyl)pentanal (14) 
To a solution of ester 13 (73.0 mg, 0.184 mmol, 1.0 equiv) in anhydrous CH2Cl2 (1.8 mL), was 
added DIBAL-H (1.0 M in CH2Cl2; 0.20 mL, 0.202 mmol, 1.1 equiv) at –78 °C. After stirring for 
1 h, the reaction was quenched by the addition of saturated aqueous potassium sodium 
tartrate (5.0 mL), stirred for 30 min and extracted with EtOAc (3 x 20 mL). The combined 
organic phases were dried over anhydrous MgSO4 and concentrated under reduced pressure. 
After purification of the crude by column chromatography (n-pentane/Et2O = 5:1), aldehyde 
14 (53.8 mg, 0.153 mmol, 83%) was obtained as colorless oil. 
14: Rf = 0.42 (n-pentane/Et2O = 6:1); [α]D25 = +11.0 (CHCl3, c = 1.05); IR:  ṽ = 835, 1110, 1152, 
1204, 1252, 1428, 1461, 1594, 1724, 2856, 2929, 2952 cm-1; 1H (500 MHz, CDCl3): δ = 9.70 (t, 
J = 1.6 Hz, 1H), 6.50 – 6.17 (m, 3H), 3.77 (s, 6H), 3.72 (dd, J = 9.9, 5.4 Hz, 1H), 3.66 (dd, J = 10.0, 
7.4 Hz, 1H), 2.66 (ddt, J = 10.2, 7.4, 5.1 Hz, 1H), 2.36 (td, J = 7.8, 1.4 Hz, 2H), 2.29 – 2.07 (m, 
1H), 1.91 – 1.74 (m, 1H), 0.87 (s, 9H), ‒0.01 (s, 3H), ‒0.02 (s, 3H) ppm; 13C (125 MHz, CDCl3): δ 
= 202.5, 161.0 (2C), 144.6, 106.4 (2C), 98.6, 67.9, 55.4 (2C), 48.4, 42.2, 26.0 (3C), 24.5, 18.4, ‒
5.3 (2C) ppm; HRMS (ESI): [M+H]+ calculated for C19H32O5SiH+: 353.2143, found: 353.2161. 
 
Synthesis of (S)-(5,7-dimethoxy-1,2,3,4-tetrahydronaphtha-len-1-yl)methanol (3) 
A solution of aldehyde 14 (53.8 mg, 0.153 mmol, 1.0 equiv) in anhydrous PhMe (5.2 mL) was 
treated with pTSA∙H2O (28.5 mg, 0.153 mmol, 1.0 equiv). The reaction was stirred for 1 h at 
23 °C and quenched with saturated aqueous NaHCO3 (5.0 mL). The mixture was extracted with 




anhydrous MgSO4, and concentrated under reduced pressure. The crude product was purified 
by column chromatography (n-pentane/Et2O = 8:1) giving the corresponding 3,4-alkene 
(45.1 mg, 0.135 mmol, 88%) as colorless oil.  
Rf = 0.78 (n-pentane/Et2O = 5:1); [α]D25 = +1.77 (CHCl3, c = 0.93); IR: ṽ = 833, 1092, 1148, 
1207, 1319, 1425, 1463, 1576, 1603, 2856, 2928, 2952 cm-1; 1H (500 MHz, CDCl3): δ = 6.71 (dd, 
J = 9.8, 2.9 Hz, 1H), 6.35 (d, J = 2.3 Hz, 1H), 6.32 (d, J = 2.3 Hz, 1H), 5.73 (ddd, J = 9.5, 5.9, 2.8 Hz, 
1H), 3.81 (s, 3H), 3.80 (s, 3H), 3.65 – 3.44 (m, 2H), 2.89 – 2.82 (m, 1H), 2.51 (ddd, J = 17.4, 6.0, 
2.6 Hz, 1H), 2.42 – 2.29 (m, 1H), 0.89 (s, 9H), 0.00 (s, 6H) ppm; 13C (125 MHz, CDCl3): δ = 159.5, 
156.0, 138.5, 122.7, 120.7, 116.2, 105.8, 97.0, 64.5, 55.7, 55.5, 41.0, 26.1 (3C), 24.3, 18.5, ‒
5.2, ‒5.3 ppm.; HRMS (ESI): [M+H]+ calculated for C19H30O3SiH+: 335.2037, found: 335.2054; 
[M+Na]+ calculated for C19H30O3SiNa+: 357.1856, found: 357.1869. 
A mixture of the intermediate alkene (45.1 mg, 0.135 mmol, 1.0 equiv) and Pd/C (5.40 mg, 
40 mg/mmol, 10% w/w) in MeOH (1.0 mL) was stirred under H2 atmosphere for 16 h at 23 °C. 
To the mixture EtOAc (80 mL) was added and the suspension filtered through a pad of Celite. 
The filtrate was concentrated under reduced pressure and the residue purified by column 
chromatography (n-pentane/EtOAc = 3:1) giving alcohol 3 (22.5 mg, 0.101 mmol, 75%) as 
colorless oil. 
3: Rf = 0.28 (n-pentane/EtOAc = 3:1); [α]D25 = –2.2 (CHCl3, c = 1.0); 1H (500 MHz, CDCl3): δ = 
6.39 (d, J = 2.2 Hz, 1H), 6.32 (d, J = 2.3 Hz, 1H), 3.81 (d, J = 6.3 Hz, 2H), 3.79 (s, 6H), 2.92 (p, J = 
5.4 Hz, 1H), 2.62 (dt, J = 16.9, 5.1 Hz, 1H), 2.53 – 2.42 (m, 1H), 1.95 – 1.86 (m, 1H), 1.81 (dd, J 
= 10.5, 3.6 Hz, 2H), 1.75 – 1.69 (m, 1H), 1.47 (brs, 1H) ppm; 13C (125 MHz, CDCl3): δ = 158.3, 




ol (16)  
To a solution of alcohol 3 (23.0 mg, 0.103 mmol, 1.5 equiv) in anhydrous CH2Cl2 (1.0 mL), 
NaHCO3 (13.0 mg, 0.152 mmol, 2.2 equiv) and DMP (44.0 mg, 0.104 mmol, 1.5 equiv) were 
added at 0 °C. The mixture was stirred for 1 h and then concentrated under reduced pressure. 
The obtained residue was purified by column chromatography (n-pentane/EtOAc = 3:1; Rf = 
0.75 (n-pentane/EtOAc = 3:1)) to give aldehyde 15 which was immediately used in the 
following step. 
nBuLi (2.5 M in hexane; 60 µL, 0.138 mmol, 2.0 equiv) was added to a solution of vinyl iodide 
2 (27.0 mg, 0.0690 mmol, 1.0 equiv) in anhydrous Et2O (1.2 mL) at ‒78 °C. After 1 h, the freshly 
prepared aldehyde 15 in Et2O (1.2 mL) was added and the reaction was stirred for 16 h at the 
same temperature.  The mixture was quenched with saturated aqueous NH4Cl (5.0 mL) and 
extracted with EtOAc (4 x 15 mL). The combined organic phases were dried over anhydrous 




chromatography (n-pentane/EtOAc =10:1), vinyl alcohol 16 (34.7 mg, 0.0721 mmol, 70%) was 
obtained as colorless oil. 
16: Rf = 0.24 (n-pentane/EtOAc = 9:1); [α]D25 = +20.6 (CHCl3, c = 1.60); 1H (500 MHz, CDCl3): 
δ = 6.48 (d, J = 2.0 Hz, 1H), 6.32 (d, J = 2.1 Hz, 1H), 5.39 (brs, 1H), 5.30 (d, J = 8.0 Hz, 1H), 4.76 
(ddd, J = 7.8, 4.7, 2.8 Hz, 1H), 3.79 (s, 3H), 3.78 (s, 3H), 2.88 – 2.79 (m, 1H), 2.62 (dt, J = 16.7, 
6.4 Hz, 1H), 2.51 (dt, J = 17.0, 6.3 Hz, 1H), 2.21 (td, J = 13.2, 12.6, 4.5 Hz, 1H), 2.02 – 1.74 (m, 
8H), 1.69 (s, 3H), 1.66 – 1.60 (m, 2H), 1.58 (s, 3H), 1.49 – 1.30 (m, 4H), 1.29 – 1.12 (m, 3H), 0.97 
– 0.92 (m, 1H), 0.88 (s, 3H), 0.85 (s, 3H), 0.75 (s, 3H) ppm; 13C (125 MHz, CDCl3): δ = 158.5 (2C), 
139.3, 138.9, 135.7, 126.2, 122.7, 120.7, 105.0, 96.4, 72.0, 55.7 (2C), 55.0, 50.6, 44.6, 42.7, 
42.6, 39.6, 37.2, 33.6, 33.4, 26.1, 24.2, 23.8, 23.0, 22.6, 22.3, 20.6, 19.2, 17.2, 13.9 ppm.  
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HPLC-Analysis of 10 was performed using Chriralpeak IA, 2% EtOH/heptane, 20 °C, 0.8 mL/min 
1) Racemic mixture 
 
 










HPLC-Analysis of 11 was performed using Chiralpeak IC, 1% isopropyl alcohol/hexane, 20 °C, 
0.8 mL/min 




























































































6.1.3 Mechanistic Studies on the Organocatalytic α-Chlorination of Aldehydes: The Role and 
Nature of Off-Cycle Intermediates 
The supporting information was slightly changed in comparison to the published version (no 
page numbers and Wiley template). The pages and the page width were adjusted to the 
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6.3 Curriculum vitae 
Der Lebenslauf ist aus Gründen des Datenschutzes nicht enthalten. 
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